Persistent	O
use	O
of	O
psychotropic	O
drugs	O
in	O
nursing	O
home	O
residents	O
in	O
Norway	O

Background	O

The	O
prevalence	O
of	O
psychotropic	O
drug	O
(	O
PTD	O
)	O
use	O
in	O
NH	O
residents	O
is	O
high	O
,	O
but	O
few	O
have	O
explored	O
prevalence	O
and	O
persistency	O
in	O
PTD	O
in	O
NH	O
residents	O
and	O
factors	O
associated	O
with	O
persistency	O
.	O

This	O
at	O
the	O
same	O
time	O
as	O
we	O
know	O
that	O
risk	O
of	O
side	O
events	O
may	O
be	O
higher	O
with	O
long	O
-	O
term	O
use	O
in	O
older	O
adults	O
.	O

Thus	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
prevalence	O
and	O
persistence	O
in	O
use	O
of	O
PTD	O
and	O
to	O
explore	O
factors	O
associated	O
with	O
persistence	O
in	O
use	O
of	O
PTD	O
at	O
two	O
consecutive	O
time	O
points	O
in	O
nursing	O
home	O
(	O
NH	O
)	O
residents	O
.	O

Methods	O

We	O
included	O
1163	O
NH	O
residents	O
in	O
a	O
72	O
-	O
month	O
longitudinal	O
study	O
with	O
five	O
assessments	O
.	O

Use	O
of	O
PTD	O
,	O
neuropsychiatric	O
symptoms	O
(	O
NPS	O
),	O
severity	O
of	O
dementia	B-DS
and	O
physical	O
health	O
were	O
assessed	O
each	O
time	O
.	O

Results	O

The	O
prevalence	O
over	O
time	O
and	O
persistent	O
use	O
of	O
antipsychotic	O
drugs	O
,	O
antidepressants	O
,	O
anxiolytics	O
and	O
sedatives	O
at	O
two	O
consecutive	O
time	O
points	O
were	O
high	O
in	O
residents	O
with	O
and	O
without	O
dementia	B-DS
.	O

There	O
was	O
an	O
association	O
between	O
greater	O
NPS	O
at	O
the	O
first	O
time	O
point	O
,	O
and	O
persistent	O
use	O
of	O
these	O
drugs	O
,	O
but	O
changes	O
in	O
NPS	O
between	O
time	O
points	O
,	O
did	O
not	O
explain	O
such	O
use	O
.	O

A	O
longer	O
NH	O
stay	O
increased	O
the	O
odds	O
for	O
persistent	O
use	O
of	O
antipsychotics	O
.	O

Conclusion	O

Psychotropic	O
drugs	O
are	O
frequently	O
used	O
as	O
a	O
long	O
-	O
term	O
treatment	O
among	O
NH	O
residents	O
and	O
are	O
associated	O
with	O
severity	O
of	O
neuropsychiatric	O
symptoms	O
,	O
but	O
not	O
with	O
severity	O
of	O
dementia	B-DS
.	O

Closer	O
attention	O
should	O
be	O
paid	O
to	O
follow	O
-	O
up	O
of	O
psychotropic	O
drug	O
treatment	O
,	O
and	O
especially	O
for	O
long	O
–	O
term	O
use	O
of	O
antipsychotics	O
,	O
since	O
the	O
duration	O
of	O
such	O
treatment	O
should	O
be	O
as	O
short	O
as	O
possible	O
.	O

Background	O

The	O
use	O
of	O
psychotropic	O
drugs	O
in	O
European	O
nursing	O
homes	O
(	O
NH	O
)	O
is	O
reported	O
to	O
be	O
quite	O
common	O
.	O

The	O
prevalence	O
of	O
use	O
of	O
any	O
psychotropic	O
drug	O
(	O
PTD	O
)	O
varied	O
between	O
42	O
and	O
80	O
%	O
in	O
studies	O
published	O
from	O
2005	O
to	O
2013	O
[	O
1	O
–	O
6	O
]	O
and	O
varied	O
between	O
countries	O
[	O
7	O
,	O
8	O
].	O

Among	O
NH	O
residents	O
with	O
dementia	B-DS
or	O
cognitive	B-DS
impairment	I-DS
,	O
the	O
prevalence	O
of	O
any	O
PTD	O
use	O
is	O
similar	O
or	O
even	O
higher	O
than	O
among	O
those	O
with	O
normal	O
cognition	O
(	O
48	O
–	O
90	O
%)	O
[	O
9	O
–	O
14	O
]	O
and	O
also	O
higher	O
than	O
in	O
community	O
living	O
older	O
adults	O
with	O
dementia	B-DS
[	O
14	O
].	O

In	O
NHs	O
in	O
Scandinavia	O
,	O
the	O
use	O
of	O
any	O
PTD	O
is	O
also	O
high	O
(	O
57	O
–	O
80	O
%)	O
[	O
15	O
–	O
19	O
],	O
especially	O
in	O
studies	O
that	O
only	O
include	O
residents	O
with	O
dementia	B-DS
(	O
68	O
–	O
85	O
%)	O
[	O
12	O
,	O
15	O
,	O
17	O
,	O
20	O
,	O
21	O
].	O

Over	O
the	O
years	O
there	O
has	O
been	O
an	O
increase	O
in	O
use	O
of	O
PTD	O
in	O
NH	O
[	O
12	O
,	O
18	O
,	O
22	O
–	O
28	O
]	O
except	O
for	O
antipsychotic	O
drugs	O
,	O
where	O
a	O
decrease	O
has	O
been	O
observed	O
in	O
recent	O
years	O
[	O
18	O
,	O
27	O
,	O
29	O
,	O
30	O
].	O

Thus	O
,	O
the	O
prevalence	O
of	O
antipsychotic	O
drug	O
use	O
in	O
Scandinavian	O
NH	O
residents	O
with	O
dementia	B-DS
is	O
among	O
the	O
lowest	O
in	O
Europe	O
(	O
pooled	O
estimates	O
24	O
%)	O
[	O
31	O
].	O

Antidepressants	O
are	O
the	O
most	O
commonly	O
used	O
PTD	O
in	O
Norwegian	O
NH	O
residents	O
[	O
16	O
,	O
18	O
,	O
22	O
].	O

Antipsychotic	O
drugs	O
are	O
often	O
used	O
to	O
treat	O
neuropsychiatric	O
symptoms	O
,	O
such	O
as	O
aggression	O
,	O
agitation	O
or	O
psychotic	O
symptoms	O
in	O
NH	O
residents	O
with	O
dementia	B-DS
,	O
although	O
non	O
-	O
pharmacological	O
interventions	O
should	O
be	O
the	O
first	O
choice	O
of	O
treatment	O
for	O
these	O
symptoms	O
[	O
32	O
,	O
33	O
].	O

However	O
,	O
in	O
demanding	O
clinical	O
situations	O
,	O
antipsychotic	O
drugs	O
may	O
be	O
unavoidable	O
,	O
but	O
there	O
is	O
no	O
evidence	O
that	O
long	O
-	O
term	O
use	O
of	O
antipsychotic	O
drugs	O
in	O
the	O
management	O
of	O
neuropsychiatric	O
symptoms	O
is	O
effective	O
[	O
33	O
].	O

Older	O
NH	O
residents	O
with	O
dementia	B-DS
can	O
be	O
withdrawn	O
from	O
long	O
-	O
term	O
antipsychotics	O
without	O
detrimental	O
effects	O
on	O
their	O
behavior	O
,	O
but	O
caution	O
is	O
required	O
in	O
residents	O
with	O
severe	O
neuropsychiatric	O
symptoms	O
[	O
34	O
].	O

Furthermore	O
,	O
the	O
duration	O
of	O
antipsychotic	O
drug	O
treatment	O
should	O
be	O
as	O
short	O
as	O
possible	O
,	O
because	O
of	O
the	O
high	O
risk	O
of	O
side	O
effects	O
[	O
32	O
],	O
such	O
as	O
more	O
rapid	O
progression	O
of	O
dementia	B-DS
[	O
9	O
]	O
or	O
cognitive	B-DS
decline	I-DS
[	O
35	O
],	O
higher	O
risk	O
of	O
cerebrovascular	O
events	O
[	O
36	O
]	O
and	O
increased	O
risk	O
of	O
falling	O
[	O
37	O
].	O

Use	O
of	O
antipsychotic	O
drugs	O
is	O
also	O
associated	O
with	O
increased	O
mortality	O
risk	O
[	O
38	O
].	O

While	O
the	O
side	O
effects	O
of	O
antipsychotics	O
have	O
received	O
the	O
most	O
attention	O
,	O
studies	O
show	O
that	O
there	O
are	O
serious	O
short	O
-	O
and	O
long	O
-	O
term	O
side	O
effects	O
such	O
as	O
falls	O
and	O
fall	O
-	O
related	O
fractures	O
associated	O
with	O
use	O
of	O
antidepressants	O
and	O
with	O
use	O
of	O
benzodiazepines	O
[	O
37	O
].	O

The	O
efficacy	O
of	O
antidepressants	O
on	O
depression	B-DS
in	O
persons	O
with	O
dementia	B-DS
was	O
not	O
confirmed	O
in	O
a	O
meta	O
-	O
analysis	O
summarizing	O
many	O
randomized	O
control	O
trials	O
[	O
39	O
].	O

A	O
recent	O
study	O
of	O
discontinuation	O
of	O
antidepressants	O
in	O
NH	O
residents	O
with	O
dementia	B-DS
and	O
neuropsychiatric	O
symptoms	O
in	O
Norway	O
found	O
that	O
most	O
residents	O
(	O
85	O
%)	O
tolerated	O
discontinuation	O
[	O
40	O
].	O

However	O
,	O
when	O
antidepressants	O
are	O
discontinued	O
in	O
residents	O
with	O
dementia	B-DS
they	O
should	O
be	O
monitored	O
carefully	O
to	O
identify	O
those	O
with	O
worsening	O
depressive	O
symptoms	O
[	O
40	O
].	O

Authors	O
who	O
studied	O
retrospectively	O
discontinuation	O
of	O
long	O
-	O
term	O
use	O
of	O
benzodiazepines	O
in	O
older	O
adults	O
with	O
and	O
without	O
dementia	B-DS
in	O
care	O
institutions	O
found	O
limited	O
evidence	O
of	O
adverse	O
outcomes	O
due	O
to	O
discontinuation	O
of	O
benzodiazepines	O
,	O
but	O
close	O
attention	O
should	O
be	O
paid	O
to	O
the	O
possibility	O
of	O
emergent	O
agitation	O
and	O
in	O
patients	O
with	O
anxiety	B-DS
caution	O
should	O
be	O
practiced	O
[	O
41	O
].	O

Discontinuation	O
of	O
long	O
-	O
term	O
use	O
of	O
Benzodiazepines	O
in	O
older	O
adults	O
without	O
dementia	B-DS
has	O
been	O
found	O
to	O
increase	O
handgrip	O
strength	O
,	O
balance	O
and	O
cognitive	O
function	O
[	O
42	O
–	O
44	O
].	O

Of	O
the	O
approximately	O
75	O
studies	O
on	O
PTD	O
in	O
NH	O
facilities	O
published	O
after	O
2004	O
,	O
only	O
a	O
small	O
fraction	O
have	O
examined	O
use	O
of	O
PTD	O
in	O
a	O
longitudinal	O
design	O
[	O
21	O
,	O
45	O
–	O
54	O
].	O

About	O
half	O
of	O
the	O
longitudinal	O
studies	O
have	O
studied	O
the	O
prevalence	O
of	O
different	O
types	O
of	O
PTD	O
over	O
time	O
or	O
persistent	O
use	O
at	O
two	O
time	O
points	O
[	O
21	O
,	O
45	O
–	O
48	O
,	O
50	O
,	O
52	O
],	O
but	O
very	O
few	O
have	O
studied	O
factors	O
associated	O
with	O
the	O
persistent	O
use	O
of	O
PTD	O
,	O
such	O
as	O
antipsychotic	O
drugs	O
[	O
46	O
,	O
52	O
],	O
antidepressants	O
,	O
anxiolytics	O
or	O
sedatives	O
.	O

However	O
,	O
as	O
the	O
risk	O
of	O
side	O
events	O
may	O
be	O
higher	O
with	O
long	O
-	O
term	O
use	O
[	O
32	O
,	O
33	O
]	O
and	O
is	O
decreased	O
after	O
discontinuation	O
of	O
PTD	O
in	O
older	O
adults	O
[	O
34	O
,	O
55	O
]	O
it	O
is	O
of	O
vital	O
importance	O
to	O
study	O
the	O
persistent	O
use	O
of	O
PTD	O
and	O
its	O
associated	O
factors	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
prevalence	O
and	O
persistence	O
of	O
PTD	O
use	O
and	O
to	O
explore	O
factors	O
associated	O
with	O
the	O
persistence	O
in	O
use	O
of	O
PTD	O
at	O
two	O
consecutive	O
time	O
points	O
in	O
a	O
Norwegian	O
sample	O
of	O
NH	O
residents	O
.	O

Method	O

Design	O

This	O
was	O
a	O
72	O
-	O
month	O
longitudinal	O
study	O
with	O
five	O
assessments	O
.	O

Baseline	O
assessment	O
(	O
A1	O
)	O
took	O
place	O
between	O
November	O
2004	O
and	O
January	O
2005	O
[	O
56	O
].	O

The	O
follow	O
-	O
up	O
assessments	O
took	O
place	O
after	O
12	O
,	O
31	O
and	O
52	O
and	O
72	O
months	O
(	O
A2	O
–	O
A5	O
).	O

Setting	O
and	O
participants	O

In	O
total	O
,	O
Norway	O
has	O
40	O
,	O
000	O
NH	O
places	O
(	O
beds	O
)	O
[	O
57	O
]	O
for	O
a	O
population	O
of	O
about	O
five	O
million	O
,	O
with	O
about	O
14	O
%	O
(	O
700	O
,	O
000	O
)	O
of	O
those	O
aged	O
65	O
years	O
or	O
older	O
[	O
58	O
].	O

The	O
jurisdiction	O
for	O
public	O
health	O
care	O
services	O
lies	O
with	O
local	O
municipalities	O
,	O
and	O
local	O
authorities	O
offer	O
social	O
services	O
(	O
such	O
as	O
housing	O
and	O
home	O
services	O
),	O
in	O
-	O
home	O
nursing	O
and	O
institutional	O
care	O
(	O
mainly	O
in	O
NHs	O
),	O
and	O
provide	O
both	O
long	O
-	O
and	O
short	O
-	O
term	O
care	O
and	O
rehabilitation	O
.	O

This	O
study	O
recruited	O
participants	O
from	O
26	O
NHs	O
in	O
18	O
municipalities	O
.	O

The	O
selection	O
of	O
small	O
,	O
medium	O
,	O
and	O
large	O
municipalities	O
was	O
made	O
to	O
obtain	O
a	O
wide	O
variety	O
of	O
NH	O
-	O
settings	O
in	O
the	O
sample	O
.	O

NH	O
residents	O
with	O
a	O
stay	O
of	O
at	O
least	O
14	O
days	O
were	O
eligible	O
for	O
inclusion	O
,	O
no	O
other	O
inclusion	O
or	O
exclusion	O
criteria	O
were	O
used	O
[	O
56	O
].	O

In	O
all	O
,	O
1165	O
residents	O
were	O
eligible	O
for	O
inclusion	O
and	O
only	O
two	O
declined	O
to	O
participate	O
.	O

Measures	O

Psychotropic	O
drugs	O
were	O
grouped	O
according	O
to	O
the	O
Anatomical	O
Therapeutic	O
Chemical	O
(	O
ATC	O
)	O
Classification	O
System	O
into	O
the	O
following	O
groups	O
:	O
antipsychotics	O
(	O
N05A	O
except	O
lithium	O
),	O
antidepressants	O
(	O
N06A	O
),	O
anxiolytics	O
(	O
N05B	O
),	O
hypnotics	O
/	O
sedatives	O
(	O
N05C	O
),	O
and	O
anti	O
-	O
dementia	B-DS
medication	O
(	O
N06D	O
)	O
(	O
yes	O
versus	O
no	O
)	O
[	O
59	O
].	O

Combination	O
drugs	O
outside	O
ATC	O
NO5B	O
and	O
NO5Cwere	O
not	O
included	O
.	O

The	O
information	O
was	O
collected	O
from	O
the	O
medical	O
record	O
of	O
each	O
resident	O
[	O
56	O
].	O

Dementia	B-DS
and	O
severity	O
of	O
dementia	B-DS
was	O
assessed	O
using	O
the	O
Clinical	O
Dementia	B-DS
Rating	O
(	O
CDR	O
)	O
scale	O
,	O
covering	O
six	O
domains	O
(	O
memory	O
;	O
orientation	O
;	O
judgment	O
and	O
problem	O
solving	O
;	O
community	O
affairs	O
;	O
home	O
and	O
hobbies	O
;	O
and	O
personal	O
care	O
)	O
with	O
five	O
response	O
categories	O
(	O
0	O
,	O
0	O
.	O
5	O
,	O
1	O
,	O
2	O
,	O
3	O
)	O
[	O
60	O
,	O
61	O
].	O

The	O
total	O
score	O
was	O
calculated	O
using	O
an	O
algorithm	O
that	O
gives	O
priority	O
to	O
memory	O
[	O
60	O
].	O

Residents	O
with	O
a	O
total	O
score	O
of	O
one	O
or	O
higher	O
were	O
regarded	O
as	O
having	O
dementia	B-DS
.	O

The	O
cut	O
-	O
off	O
CDR	O
≥	O
1	O
in	O
defining	O
dementia	B-DS
has	O
been	O
found	O
adequate	O
in	O
previous	O
Norwegian	O
and	O
international	O
studies	O
[	O
62	O
–	O
64	O
].	O

The	O
categorical	O
scores	O
indicate	O
the	O
severity	O
of	O
dementia	B-DS
:	O
a	O
CDR	O
score	O
of	O
1	O
represents	O
mild	B-DS
dementia	I-DS
,	O
a	O
CDR	O
score	O
of	O
2	O
represents	O
moderate	B-DS
dementia	I-DS
,	O
and	O
a	O
CDR	O
score	O
of	O
3	O
represents	O
severe	B-DS
dementia	I-DS
.	O

The	O
sum	O
-	O
score	O
of	O
the	O
six	O
domains	O
(	O
sum	O
of	O
boxes	O
),	O
ranging	O
from	O
zero	O
to	O
18	O
,	O
can	O
also	O
be	O
used	O
to	O
measure	O
the	O
severity	O
of	O
dementia	B-DS
,	O
as	O
the	O
categorical	O
and	O
continuous	O
scores	O
correlate	O
highly	O
≥	O
0	O
.	O
9	O
[	O
65	O
,	O
66	O
].	O

The	O
Spearman	O
correlation	O
between	O
the	O
categorical	O
CDR	O
score	O
and	O
the	O
CDR	O
sum	O
of	O
boxes	O
score	O
in	O
the	O
present	O
study	O
was	O
0	O
.	O
93	O
.	O

Due	O
to	O
a	O
wider	O
range	O
of	O
values	O
,	O
the	O
CDR	O
sum	O
of	O
boxes	O
offers	O
important	O
advantages	O
when	O
analyzing	O
the	O
data	O
[	O
66	O
].	O

We	O
used	O
the	O
CDR	O
score	O
(	O
CDR	O
≥	O
1	O
)	O
as	O
an	O
indication	O
of	O
dementia	B-DS
,	O
as	O
it	O
was	O
not	O
possible	O
to	O
perform	O
a	O
standardized	O
dementia	B-DS
work	O
-	O
up	O
for	O
all	O
residents	O
because	O
many	O
were	O
too	O
frail	O
or	O
mentally	O
impaired	O
to	O
take	O
part	O
in	O
examinations	O
such	O
as	O
CT	O
or	O
MRI	O
.	O

A	O
large	O
number	O
of	O
residents	O
with	O
a	O
CDR	O
score	O
of	O
3	O
could	O
not	O
be	O
tested	O
with	O
any	O
dementia	B-DS
tests	O
such	O
as	O
the	O
Mini	O
Mental	O
Status	O
Examination	O
[	O
67	O
]	O
or	O
the	O
Clock	O
Drawing	O
Test	O
[	O
68	O
].	O

Physical	O
health	O
was	O
assessed	O
using	O
the	O
General	O
Medical	O
Health	O
Rating	O
(	O
GMHR	O
)	O
scale	O
[	O
69	O
].	O

This	O
is	O
a	O
one	O
-	O
item	O
global	O
rating	O
scale	O
with	O
four	O
categories	O
:	O
good	O
,	O
fairly	O
good	O
,	O
poor	O
,	O
and	O
very	O
poor	O
.	O

The	O
rating	O
was	O
based	O
on	O
all	O
available	O
information	O
on	O
physical	O
health	O
and	O
use	O
of	O
drugs	O
.	O

The	O
scale	O
has	O
been	O
used	O
in	O
large	O
studies	O
including	O
older	O
people	O
with	O
and	O
without	O
dementia	B-DS
[	O
70	O
]	O
and	O
has	O
been	O
translated	O
and	O
used	O
in	O
several	O
studies	O
[	O
71	O
,	O
72	O
].	O

The	O
Personal	O
Activities	O
of	O
Daily	O
Living	O
(	O
P	O
-	O
ADL	O
)	O
score	O
was	O
assessed	O
with	O
the	O
Physical	O
Self	O
-	O
Maintenance	O
Scale	O
(	O
PSMS	O
),	O
including	O
six	O
items	O
,	O
with	O
a	O
total	O
score	O
ranging	O
from	O
6	O
to	O
30	O
[	O
73	O
].	O

High	O
scores	O
indicate	O
a	O
lower	O
level	O
of	O
functioning	O
.	O

Neuropsychiatric	O
symptoms	O
(	O
NPS	O
)	O
were	O
assessed	O
using	O
the	O
Neuropsychiatric	O
Inventory	O
Nursing	O
Home	O
version	O
(	O
NPI	O
-	O
NH	O
)	O
[	O
74	O
,	O
75	O
].	O

The	O
10	O
-	O
item	O
inventory	O
covers	O
the	O
following	O
symptoms	O
:	O
delusion	B-DS
,	O
hallucination	B-DS
,	O
euphoria	O
,	O
agitation	O
/	O
aggression	O
,	O
disinhibition	O
,	O
irritability	O
/	O
lability	O
,	O
depression	B-DS
/	O
dysphoria	B-DS
,	O
anxiety	B-DS
,	O
apathy	O
/	O
indifference	O
,	O
and	O
aberrant	O
motor	O
behavior	O
(	O
no	O
/	O
yes	O
).	O

For	O
each	O
symptom	O
,	O
severity	O
(	O
score	O
1	O
–	O
3	O
)	O
multiplied	O
by	O
frequency	O
(	O
score	O
1	O
–	O
4	O
)	O
provides	O
a	O
score	O
from	O
zero	O
to	O
12	O
.	O

Based	O
on	O
a	O
previous	O
principal	O
component	O
analysis	O
,	O
psychosis	B-DS
(	O
delusions	B-DS
,	O
hallucination	B-DS
),	O
agitation	O
(	O
agitation	O
/	O
aggression	O
,	O
disinhibition	O
,	O
irritability	O
),	O
and	O
affective	O
(	O
depression	B-DS
,	O
anxiety	B-DS
)	O
sub	O
-	O
syndrome	O
scores	O
were	O
formed	O
by	O
summing	O
the	O
score	O
of	O
the	O
included	O
items	O
[	O
76	O
–	O
79	O
].	O

The	O
apathy	O
/	O
indifference	O
was	O
analyzed	O
as	O
a	O
single	O
symptom	O
.	O

Demographic	O
information	O
such	O
as	O
age	O
,	O
gender	O
,	O
marital	O
status	O
,	O
and	O
length	O
of	O
stay	O
in	O
the	O
NH	O
at	O
the	O
time	O
of	O
inclusion	O
was	O
collected	O
from	O
medical	O
records	O
.	O

The	O
type	O
of	O
unit	O
was	O
also	O
recorded	O
from	O
among	O
the	O
following	O
options	O
:	O
regular	O
units	O
(	O
RU	O
),	O
special	O
care	O
unit	O
for	O
people	O
with	O
dementia	B-DS
(	O
SCU	O
),	O
rehabilitation	O
unit	O
(	O
REU	O
),	O
and	O
other	O
units	O
(	O
OU	O
),	O
mainly	O
psychogeriatric	O
wards	O
.	O

The	O
length	O
of	O
stay	O
in	O
a	O
NH	O
before	O
study	O
inclusion	O
was	O
measured	O
in	O
days	O
.	O

Procedure	O

Nurses	O
with	O
extensive	O
clinical	O
experience	O
collected	O
the	O
data	O
.	O

Prior	O
to	O
data	O
collection	O
,	O
all	O
assessors	O
participated	O
in	O
a	O
2	O
-	O
day	O
course	O
on	O
how	O
to	O
apply	O
the	O
standardized	O
questionnaires	O
.	O

A	O
1	O
-	O
day	O
training	O
program	O
was	O
carried	O
out	O
prior	O
to	O
each	O
follow	O
-	O
up	O
assessment	O
.	O

The	O
project	O
leader	O
(	O
GS	O
)	O
was	O
available	O
for	O
consultation	O
throughout	O
the	O
data	O
collection	O
period	O
.	O

The	O
nurses	O
collected	O
data	O
from	O
medical	O
records	O
and	O
via	O
a	O
standardized	O
interview	O
with	O
the	O
residents	O
’	O
primary	O
caregivers	O
,	O
all	O
of	O
whom	O
were	O
registered	O
nurses	O
.	O

All	O
assessment	O
scales	O
used	O
were	O
standard	O
translated	O
Norwegian	O
versions	O
.	O

A	O
pilot	O
study	O
including	O
41	O
NH	O
residents	O
was	O
carried	O
out	O
to	O
test	O
inter	O
-	O
rater	O
reliability	O
of	O
CDR	O
prior	O
to	O
the	O
first	O
data	O
collection	O
and	O
the	O
inter	O
-	O
rater	O
reliability	O
was	O
very	O
good	O
.	O

The	O
kappa	O
statistics	O
for	O
the	O
global	O
CDR	O
score	O
were	O
1	O
(	O
between	O
geriatric	O
psychiatrist	O
and	O
registered	O
nurse	O
specialized	O
in	O
psychiatry	O
)	O
and	O
0	O
.	O
86	O
(	O
between	O
geriatric	O
psychiatrist	O
and	O
registered	O
nurse	O
).	O

More	O
detailed	O
information	O
of	O
the	O
inter	O
-	O
rating	O
reliability	O
test	O
has	O
been	O
published	O
elsewhere	O
[	O
56	O
].	O

Study	O
information	O
was	O
given	O
to	O
the	O
residents	O
and	O
their	O
family	O
members	O
.	O

The	O
residents	O
and	O
their	O
next	O
of	O
kin	O
were	O
informed	O
that	O
they	O
could	O
refuse	O
to	O
participate	O
at	O
any	O
stage	O
of	O
the	O
study	O
.	O

This	O
procedure	O
was	O
recommended	O
and	O
approved	O
by	O
the	O
Regional	O
Ethics	O
Committee	O
in	O
the	O
south	O
east	O
of	O
Norway	O
,	O
the	O
Data	O
Inspectorate	O
and	O
the	O
Directorate	O
for	O
Health	O
and	O
Social	O
Affairs	O
in	O
2004	O
before	O
data	O
collection	O
.	O

Data	O
analysis	O

Sample	O
characteristics	O
at	O
baseline	O
were	O
described	O
as	O
means	O
and	O
standard	O
deviations	O
(	O
SD	O
)	O
or	O
frequencies	O
and	O
percentages	O
.	O

Residents	O
with	O
CDR	O
≥	O
1	O
and	O
CDR	O
<	O
1	O
were	O
compared	O
by	O
Independent	O
samples	O
t	O
-	O
test	O
for	O
continuous	O
and	O
χ2	O
-	O
test	O
for	O
categorical	O
variables	O
.	O

Prevalence	O
and	O
persistence	O
of	O
PTD	O
use	O
among	O
those	O
with	O
and	O
without	O
dementia	B-DS
were	O
compared	O
by	O
Z	O
-	O
test	O
for	O
proportions	O
.	O

The	O
persistence	O
in	O
outcomes	O
,	O
use	O
of	O
antipsychotics	O
,	O
antidepressants	O
,	O
anxiolytics	O
and	O
sedatives	O
were	O
assessed	O
with	O
a	O
logistic	O
regression	O
model	O
for	O
hierarchical	O
data	O
(	O
SAS	O
GLIMMIX	O
procedure	O
).	O

Random	O
effects	O
for	O
type	O
of	O
unit	O
nested	O
in	O
a	O
NH	O
were	O
included	O
into	O
the	O
model	O
.	O

The	O
dependent	O
variable	O
was	O
current	O
use	O
of	O
a	O
specific	O
type	O
of	O
PTD	O
drug	O
,	O
while	O
the	O
independent	O
variable	O
was	O
either	O
use	O
of	O
the	O
same	O
drug	O
at	O
the	O
previous	O
time	O
point	O
(	O
lag	O
1	O
),	O
two	O
time	O
points	O
previously	O
(	O
lag	O
2	O
)	O
or	O
three	O
time	O
points	O
previously	O
(	O
lag	O
3	O
).	O

All	O
models	O
were	O
adjusted	O
for	O
a	O
number	O
of	O
relevant	O
covariates	O
measured	O
at	O
the	O
same	O
time	O
point	O
as	O
the	O
independent	O
variable	O
.	O

A	O
similar	O
model	O
was	O
estimated	O
to	O
assess	O
variables	O
associated	O
to	O
persistent	O
use	O
of	O
drugs	O
,	O
where	O
the	O
outcome	O
was	O
defined	O
as	O
1	O
in	O
the	O
case	O
of	O
use	O
of	O
drugs	O
at	O
two	O
adjacent	O
time	O
points	O
and	O
0	O
otherwise	O
.	O

In	O
addition	O
,	O
exploratory	O
analyses	O
assessing	O
association	O
between	O
change	O
in	O
NPI	O
sub	O
-	O
syndromes	O
and	O
persistent	O
use	O
of	O
drugs	O
were	O
performed	O
.	O

All	O
multivariate	O
models	O
were	O
reduced	O
using	O
Akaike	O
’	O
s	O
Information	O
Criteria	O
,	O
where	O
a	O
lower	O
value	O
means	O
a	O
better	O
model	O
.	O

The	O
results	O
were	O
tabulated	O
as	O
odds	O
ratios	O
(	O
ORs	O
)	O
with	O
corresponding	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
and	O
presented	O
graphically	O
.	O

All	O
analyses	O
were	O
performed	O
in	O
SPSS	O
version	O
22	O
and	O
SAS	O
v9	O
.	O
3	O
.	O
P	O
-	O
values	O
below	O
0	O
.	O
05	O
were	O
considered	O
statically	O
significant	O
.	O

All	O
tests	O
were	O
two	O
-	O
sided	O
.	O

Results	O

Sample	O
characteristics	O

At	O
baseline	O
,	O
the	O
mean	O
(	O
SD	O
)	O
age	O
of	O
the	O
residents	O
was	O
84	O
.	O
4	O
(	O
7	O
.	O
8	O
)	O
years	O
and	O
846	O
(	O
72	O
.	O
7	O
%)	O
of	O
them	O
were	O
women	B-OG
(	O
Table	O
1	O
).	O

The	O
mean	O
(	O
SD	O
)	O
baseline	O
CDR	O
sum	O
of	O
boxes	O
was	O
11	O
.	O
2	O
(	O
5	O
.	O
3	O
)	O
and	O
932	O
(	O
80	O
.	O
1	O
%)	O
residents	O
had	O
CDR	O
≥	O
1	O
indicating	O
dementia	B-DS
.	O

The	O
mean	O
length	O
of	O
stay	O
at	O
baseline	O
was	O
938	O
.	O
3	O
(	O
1013	O
.	O
1	O
)	O
days	O
and	O
the	O
mean	O
(	O
SD	O
)	O
number	O
of	O
prescribed	O
drugs	O
taken	O
regularly	O
was	O
6	O
.	O
0	O
(	O
3	O
.	O
1	O
).	O

Of	O
the	O
1163	O
residents	O
at	O
baseline	O
,	O
98	O
(	O
8	O
.	O
4	O
%)	O
were	O
still	O
alive	O
and	O
available	O
at	O
the	O
fifth	O
follow	O
-	O
up	O
(	O
see	O
Fig	O
.	O
1	O
).	O

Mean	O
(	O
SD	O
)	O
time	O
of	O
follow	O
-	O
up	O
was	O
829	O
.	O
5	O
(	O
690	O
.	O
0	O
)	O
days	O
.	O
Table	O
1Sample	O
characteristics	O
at	O
baselineA1CDR	O
≥	O
1CDR	O
<	O
1	O
P	O
-	O
valuesa	O
1163932Socio	O
-	O
demographics	O
AgeMean	O
(	O
SD	O
)	O
84	O
.	O
4	O
(	O
7	O
.	O
8	O
)	O
84	O
.	O
5	O
(	O
7	O
.	O
5	O
)	O
83	O
.	O
8	O
(	O
9	O
.	O
0	O
)	O
0	O
.	O
223	O
FemalesN	O
(%)	O
846	O
(	O
72	O
.	O
7	O
)	O
686	O
(	O
73	O
.	O
6	O
)	O
156	O
(	O
68	O
.	O
7	O
)	O
0	O
.	O
139	O
Education	O
<	O
10	O
yearsN	O
(%)	O
847	O
(	O
74	O
.	O
8	O
)	O
673	O
(	O
74	O
.	O
1	O
)	O
170	O
(	O
76	O
.	O
9	O
)	O
0	O
.	O
390	O
MarriedN	O
(%)	O
221	O
(	O
19	O
.	O
0	O
)	O
185	O
(	O
19	O
.	O
8	O
)	O
36	O
(	O
15	O
.	O
9	O
)	O
0	O
.	O
178Health	O
condition	O
GMHR	O
Good	O
Fairly	O
good	O
Poor	O
Very	O
PoorN	O
(%)	O
N	O
(%)	O
N	O
(%)	O
N	O
(%)	O
194	O
(	O
17	O
.	O
2	O
)	O
386	O
(	O
34	O
.	O
1	O
)	O
378	O
(	O
33	O
.	O
4	O
)	O
173	O
(	O
15	O
.	O
3	O
)	O
142	O
(	O
15	O
.	O
7	O
)	O
291	O
(	O
32	O
.	O
2	O
)	O
322	O
(	O
35	O
.	O
6	O
)	O
150	O
(	O
16	O
.	O
6	O
)	O
52	O
(	O
23	O
.	O
4	O
)	O
94	O
(	O
42	O
.	O
3	O
)	O
53	O
(	O
23	O
.	O
9	O
)	O
23	O
(	O
10	O
.	O
4	O
)<	O
0	O
.	O
001	O
PSMS	O
scoreMean	O
(	O
SD	O
)	O
18	O
.	O
1	O
(	O
5	O
.	O
4	O
)	O
18	O
.	O
8	O
(	O
5	O
.	O
3	O
)	O
15	O
.	O
4	O
(	O
4	O
.	O
8	O
)<	O
0	O
.	O
001	O
NPI	O
Agitation	O
sub	O
-	O
syndromeMean	O
(	O
SD	O
)	O
5	O
.	O
8	O
(	O
8	O
.	O
0	O
)	O
6	O
.	O
5	O
(	O
8	O
.	O
2	O
)	O
2	O
.	O
9	O
(	O
6	O
.	O
1	O
)<	O
0	O
.	O
001	O
NPI	O
Psychosis	B-DS
sub	O
-	O
syndromeMean	O
(	O
SD	O
)	O
2	O
.	O
8	O
(	O
5	O
.	O
1	O
)	O
3	O
.	O
2	O
(	O
5	O
.	O
3	O
)	O
1	O
.	O
3	O
(	O
3	O
.	O
8	O
)<	O
0	O
.	O
001	O
NPI	O
Affective	O
sub	O
-	O
syndromeMean	O
(	O
SD	O
)	O
3	O
.	O
5	O
(	O
5	O
.	O
3	O
)	O
3	O
.	O
7	O
(	O
5	O
.	O
4	O
)	O
2	O
.	O
9	O
(	O
4	O
.	O
9	O
)	O
0	O
.	O
041	O
NPI	O
ApathyMean	O
(	O
SD	O
)	O
2	O
.	O
2	O
(	O
3	O
.	O
7	O
)	O
2	O
.	O
4	O
(	O
3	O
.	O
8	O
)	O
1	O
.	O
1	O
(	O
2	O
.	O
9	O
)<	O
0	O
.	O
001	O
No	O
of	O
drugsMean	O
(	O
SD	O
)	O
6	O
.	O
0	O
(	O
3	O
.	O
1	O
)	O
5	O
.	O
8	O
(	O
3	O
.	O
0	O
)	O
6	O
.	O
9	O
(	O
3	O
.	O
3	O
)<	O
0	O
.	O
001	O
Days	O
in	O
NHMean	O
(	O
SD	O
)	O
938	O
.	O
3	O
(	O
1013	O
.	O
0	O
)	O
928	O
.	O
9	O
(	O
910	O
.	O
1	O
)	O
975	O
.	O
5	O
(	O
1359	O
.	O
3	O
)	O
0	O
.	O
534	O
CDR	O
Clinical	O
Dementia	B-DS
Rating	O
scale	O
GMHR	O
General	O
Medical	O
Health	O
rating	O
PSMS	O
Physical	O
Self	O
-	O
Maintenance	O
Scale	O
NPI	O
Neuropsychiatric	O
Inventory	O
NH	O
Nursing	O
home	O
aCalculated	O
by	O
using	O
t	O
-	O
test	O
for	O
Independent	O
samples	O
for	O
continuous	O
or	O
χ2	O
-	O
test	O
for	O
categorical	O
variables	O
Fig	O
.	O
1Flow	O
chart	O
.	O

Mean	O
(	O
SD	O
)	O
time	O
between	O
accessions	O
were	O
11	O
.	O
1	O
(	O
0	O
.	O
5	O
)	O
months	O
for	O
A1	O
–	O
A2	O
,	O
18	O
.	O
6	O
(	O
1	O
.	O
3	O
)	O
months	O
for	O
A2	O
–	O
A3	O
,	O
20	O
.	O
5	O
(	O
1	O
.	O
7	O
)	O
months	O
for	O
A3	O
–	O
A4	O
and	O
20	O
.	O
8	O
(	O
2	O
.	O
8	O
)	O
months	O
for	O
A4	O
–	O
A5	O

Prevalence	O
of	O
psychotropic	O
drugs	O
over	O
time	O

The	O
prevalence	O
of	O
PTD	O
use	O
at	O
baseline	O
and	O
each	O
of	O
the	O
follow	O
-	O
up	O
time	O
points	O
are	O
presented	O
in	O
Table	O
2	O
.	O

Antidepressants	O
were	O
most	O
frequently	O
used	O
(	O
38	O
.	O
3	O
%	O
at	O
baseline	O
,	O
32	O
.	O
7	O
%	O
at	O
last	O
follow	O
-	O
up	O
);	O
while	O
anti	O
-	O
dementia	B-DS
drugs	O
were	O
least	O
frequently	O
used	O
(	O
11	O
.	O
3	O
%	O
at	O
baseline	O
,	O
0	O
%	O
at	O
last	O
follow	O
-	O
up	O
).	O

The	O
prevalence	O
of	O
use	O
of	O
any	O
PTD	O
was	O
high	O
throughout	O
the	O
period	O
;	O
at	O
baseline	O
the	O
prevalence	O
was	O
72	O
.	O
9	O
%,	O
but	O
had	O
fallen	O
to	O
63	O
.	O
3	O
%	O
at	O
the	O
last	O
follow	O
-	O
up	O
.	O
Table	O
2Prevalence	O
and	O
persistence	O
of	O
PTD	O
use	O
according	O
to	O
the	O
presence	O
of	O
dementia	B-DS
at	O
each	O
assessment	O
(%)	O
Prevalence	O
in	O
percentagesA1	O
A2	O
A3	O
A4	O
A5	O
All	O
(	O
n	O
=	O
1163	O
)	O
D	O
/	O
nD	O
(	O
n	O
=	O
932	O
/	O
227	O
)	O
All	O
(	O
n	O
=	O
789	O
)	O
D	O
/	O
nD	O
(	O
n	O
=	O
628	O
/	O
159	O
)	O
All	O
(	O
n	O
=	O
395	O
)	O
D	O
/	O
nD	O
(	O
n	O
=	O
300	O
/	O
94	O
)	O
All	O
(	O
n	O
=	O
209	O
)	O
D	O
/	O
nD	O
(	O
n	O
=	O
160	O
/	O
48	O
)	O
All	O
(	O
n	O
=	O
98	O
)	O
D	O
/	O
nD	O
(	O
n	O
=	O
75	O
/	O
22	O
)	O
Antipsychotics	O
(	O
AP	O
)	O
24	O
.	O
126	O
.	O
0	O
/	O
15	O
.	O
9	O
***	O
25	O
.	O
226	O
.	O
4	O
/	O
20	O
.	O
820	O
.	O
522	O
.	O
0	O
/	O
16	O
.	O
020	O
.	O
622	O
.	O
5	O
/	O
14	O
.	O
620	O
.	O
420	O
.	O
0	O
/	O
22	O
.	O
7	O
Trad	O
.	O

AP11	O
.	O
311	O
.	O
5	O
/	O
11	O
.	O
012	O
.	O
211	O
.	O
6	O
/	O
14	O
.	O
59	O
.	O
49	O
.	O
0	O
/	O
10	O
.	O
68	O
.	O
69	O
.	O
4	O
/	O
6	O
.	O
312	O
.	O
212	O
.	O
0	O
/	O
13	O
.	O
6	O
Atypical	O
AP13	O
.	O
214	O
.	O
9	O
/	O
5	O
.	O
7	O
***	O
13	O
.	O
815	O
.	O
6	O
/	O
6	O
.	O
9	O
***	O
11	O
.	O
913	O
.	O
7	O
/	O
6	O
.	O
4	O
**	O
12	O
.	O
613	O
.	O
1	O
/	O
8	O
.	O
38	O
.	O
28	O
.	O
0	O
/	O
9	O
.	O
1Antidepressants38	O
.	O
339	O
.	O
1	O
/	O
34	O
.	O
837	O
.	O
337	O
.	O
9	O
/	O
34	O
.	O
036	O
.	O
735	O
.	O
3	O
/	O
40	O
.	O
435	O
.	O
433	O
.	O
1	O
/	O
41	O
.	O
732	O
.	O
729	O
.	O
3	O
/	O
40	O
.	O
9Anxiolytics24	O
.	O
223	O
.	O
8	O
/	O
26	O
.	O
424	O
.	O
222	O
.	O
9	O
/	O
29	O
.	O
6	O
*	O
25	O
.	O
121	O
.	O
3	O
/	O
37	O
.	O
2	O
***	O
28	O
.	O
726	O
.	O
9	O
/	O
35	O
.	O
422	O
.	O
421	O
.	O
3	O
/	O
27	O
.	O
3Sedatives29	O
.	O
026	O
.	O
4	O
/	O
39	O
.	O
6	O
***	O
26	O
.	O
623	O
.	O
4	O
/	O
38	O
.	O
4	O
***	O
24	O
.	O
121	O
.	O
0	O
/	O
33	O
.	O
0	O
*	O
23	O
.	O
919	O
.	O
4	O
/	O
37	O
.	O
5	O
**	O
23	O
.	O
520	O
.	O
0	O
/	O
31	O
.	O
8Antidementia	O
drug11	O
.	O
313	O
.	O
5	O
/	O
2	O
.	O
2	O
***	O
9	O
.	O
811	O
.	O
8	O
/	O
1	O
.	O
9	O
***	O
5	O
.	O
36	O
.	O
3	O
/	O
2	O
.	O
1	O
*	O
2	O
.	O
93	O
.	O
1	O
/	O
2	O
.	O
100	O
/	O
0Any	O
PTD72	O
.	O
974	O
.	O
5	O
/	O
66	O
.	O
5	O
*	O
71	O
.	O
471	O
.	O
5	O
/	O
70	O
.	O
470	O
.	O
467	O
.	O
7	O
/	O
78	O
.	O
7	O
*	O
69	O
.	O
466	O
.	O
9	O
/	O
77	O
.	O
163	O
.	O
357	O
.	O
3	O
/	O
81	O
.	O
8	O
**	O
Persistence	O
at	O
two	O
consecutive	O
time	O
points	O
in	O
percentagesA1	O
–	O
A2	O
A2	O
–	O
A3	O
A3	O
–	O
A4	O
A4	O
–	O
A5	O
AllD	O
/	O
nDAllD	O
/	O
nDAllD	O
/	O
nDAllD	O
/	O
nDAntipsychotics	O
(	O
AP	O
)	O
76	O
.	O
775	O
.	O
2	O
/	O
88	O
.	O
9	O
*	O
64	O
.	O
967	O
.	O
6	O
/	O
55	O
.	O
069	O
.	O
667	O
.	O
5	O
/	O
83	O
.	O
370	O
.	O
068	O
.	O
8	O
/	O
75	O
.	O
0	O
Trad	O
.	O

AP73	O
.	O
670	O
.	O
8	O
/	O
84	O
.	O
261	O
.	O
463	O
.	O
3	O
/	O
57	O
.	O
173	O
.	O
773	O
.	O
3	O
/	O
75	O
.	O
080	O
.	O
075	O
.	O
0	O
/	O
100	O
Atypical	O
AP74	O
.	O
574	O
.	O
7	O
/	O
80	O
.	O
061	O
.	O
563	O
.	O
0	O
/	O
50	O
.	O
062	O
.	O
159	O
.	O
3	O
/	O
100	O
***	O
60	O
.	O
062	O
.	O
5	O
/	O
50	O
.	O
0Antidepressants80	O
.	O
479	O
.	O
8	O
/	O
82	O
.	O
876	O
.	O
573	O
.	O
1	O
/	O
87	O
.	O
9	O
*	O
72	O
.	O
266	O
.	O
1	O
/	O
89	O
.	O
5	O
**	O
75	O
.	O
776	O
.	O
9	O
/	O
70	O
.	O
0Anxiolytics76	O
.	O
973	O
.	O
6	O
/	O
89	O
.	O
5	O
**	O
69	O
.	O
262	O
.	O
7	O
/	O
84	O
.	O
4	O
**	O
86	O
.	O
882	O
.	O
1	O
/	O
100	O
**	O
66	O
.	O
766	O
.	O
7	O
/	O
66	O
.	O
7Sedatives70	O
.	O
965	O
.	O
8	O
/	O
82	O
.	O
8	O
**	O
64	O
.	O
869	O
.	O
1	O
/	O
55	O
.	O
669	O
.	O
664	O
.	O
9	O
/	O
77	O
.	O
868	O
.	O
058	O
.	O
8	O
/	O
85	O
.	O
7Antidementia	O
drug66	O
.	O
065	O
.	O
3	O
/	O
100	O
***	O
38	O
.	O
136	O
.	O
6	O
/	O
100	O
***	O
27	O
.	O
327	O
.	O
3	O
/	O
000	O
/	O
0Any	O
PTD89	O
.	O
888	O
.	O
7	O
/	O
94	O
.	O
3	O
*	O
85	O
.	O
382	O
.	O
4	O
/	O
94	O
.	O
2	O
**	O
89	O
.	O
386	O
.	O
6	O
/	O
97	O
.	O
3	O
**	O
78	O
.	O
475	O
.	O
5	O
/	O
85	O
.	O
0A1	O
–	O
A5	O
:	O
Assessment	O
1	O
–	O
5	O
D	O
Dementia	B-DS
CDR	O
≥	O
1	O
;	O
nD	O
No	O
dementia	B-DS
CDR	O
<	O
1CDR	O
ratings	O
were	O
missing	O
for	O
4	O
people	O
at	O
A1	O
,	O
2	O
people	O
at	O
A2	O
and	O
2	O
people	O
at	O
A3	O
CDR	O
Clinical	O
Dementia	B-DS
Rating	O
scale	O
Trad	O
Conventional	O
PTD	O
Psychotropic	O
drugs	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
**	O
p	O
≤	O
0	O
.	O
01	O
;	O
***	O
p	O
≤	O
0	O
.	O
001	O
(	O
Z	O
-	O
test	O
for	O
proportions	O
used	O
)	O

At	O
baseline	O
,	O
the	O
use	O
of	O
any	O
PTD	O
occurred	O
more	O
frequently	O
in	O
residents	O
with	O
dementia	B-DS
,	O
while	O
at	O
the	O
last	O
follow	O
-	O
up	O
any	O
PTD	O
was	O
more	O
often	O
used	O
in	O
residents	O
without	O
dementia	B-DS
.	O

Atypical	O
antipsychotics	O
were	O
used	O
more	O
frequently	O
in	O
residents	O
with	O
dementia	B-DS
at	O
A1	O
–	O
A3	O
,	O
whereas	O
residents	O
without	O
dementia	B-DS
used	O
anxiolytics	O
more	O
frequently	O
at	O
A2	O
and	O
A3	O
and	O
sedatives	O
more	O
frequently	O
at	O
A1	O
–	O
A4	O
,	O
respectively	O
.	O

Persistent	O
use	O
of	O
psychotropic	O
drugs	O

The	O
proportion	O
of	O
PTD	O
use	O
at	O
two	O
consecutive	O
time	O
points	O
was	O
high	O
(>	O
50	O
%)	O
throughout	O
the	O
period	O
for	O
all	O
types	O
of	O
PTD	O
,	O
except	O
for	O
use	O
of	O
anti	O
-	O
dementia	B-DS
drugs	O
(	O
Table	O
2	O
).	O

Persistent	O
use	O
of	O
anxiolytics	O
at	O
two	O
consecutive	O
time	O
points	O
was	O
higher	O
for	O
residents	O
without	O
dementia	B-DS
than	O
those	O
with	O
dementia	B-DS
.	O

Among	O
those	O
who	O
completed	O
all	O
assessments	O
(	O
n	O
=	O
98	O
),	O
10	O
.	O
4	O
%	O
used	O
antipsychotic	O
drugs	O
,	O
19	O
.	O
8	O
%	O
used	O
antidepressants	O
,	O
11	O
.	O
5	O
%	O
used	O
anxiolytics	O
and	O
9	O
.	O
4	O
%	O
used	O
sedatives	O
at	O
all	O
assessments	O
.	O

Unadjusted	O
and	O
adjusted	O
odds	O
for	O
use	O
of	O
PTD	O
at	O
one	O
time	O
point	O
,	O
given	O
use	O
of	O
the	O
same	O
type	O
of	O
PTD	O
at	O
an	O
earlier	O
time	O
point	O
was	O
estimated	O
for	O
all	O
types	O
of	O
PTD	O
except	O
for	O
anti	O
-	O
dementia	B-DS
drug	O
use	O
(	O
Table	O
3	O
and	O
Fig	O
.	O
2	O
).	O

Both	O
in	O
unadjusted	O
and	O
adjusted	O
analyses	O
,	O
the	O
odds	O
for	O
persistent	O
use	O
of	O
antipsychotics	O
,	O
antidepressants	O
,	O
anxiolytics	O
and	O
sedative	O
were	O
high	O
.	O

The	O
odds	O
for	O
persistent	O
use	O
of	O
these	O
PTD	O
were	O
highest	O
when	O
compared	O
with	O
use	O
at	O
the	O
closest	O
earlier	O
assessment	O
time	O
point	O
(	O
Lag	O
1	O
)	O
and	O
fell	O
successively	O
when	O
the	O
distance	O
between	O
the	O
assessment	O
time	O
points	O
increased	O
(	O
Lags	O
2	O
and	O
3	O
),	O
with	O
one	O
exception	O
for	O
antipsychotics	O
where	O
the	O
odds	O
slightly	O
increased	O
when	O
there	O
were	O
three	O
time	O
points	O
between	O
assessments	O
(	O
Lag	O
3	O
)	O
compared	O
to	O
two	O
time	O
points	O
(	O
Lag	O
2	O
).	O

All	O
results	O
were	O
highly	O
significant	O
(	O
p	O
<	O
0	O
.	O
001	O
).	O
Table	O
3Odds	O
ratios	O
for	O
use	O
of	O
each	O
category	O
of	O
psychotropic	O
drugs	O
at	O
one	O
time	O
point	O
given	O
use	O
of	O
the	O
same	O
category	O
of	O
the	O
psychotropic	O
drug	O
at	O
an	O
earlier	O
time	O
point	O
(	O
the	O
distance	O
between	O
time	O
points	O
is	O
called	O
lag	O
),	O
unadjusted	O
and	O
adjusted	O
analyses	O
where	O
relevant	O
covariates	O
adjusted	O
for	O
were	O
measured	O
at	O
the	O
same	O
earlier	O
timeVariablesUnadjustedAdjustedOR	O
(	O
95	O
%	O
CI	O
)	O
P	O
-	O
valueOR	O
(	O
95	O
%	O
CI	O
)	O
P	O
-	O
valueLag	O
1	O
,	O
N	O
=	O
1406	O
observations	O
Antipsychoticsa	O
30	O
.	O
7	O
(	O
21	O
.	O
8	O
;	O
43	O
.	O
1	O
)<	O
0	O
.	O
00128	O
.	O
8	O
(	O
20	O
.	O
31	O
;	O
40	O
.	O
8	O
)<	O
0	O
.	O
001	O
Antidepressantsb	O
32	O
.	O
6	O
(	O
23	O
.	O
8	O
;	O
44	O
.	O
8	O
)<	O
0	O
.	O
00134	O
.	O
1	O
(	O
24	O
.	O
6	O
;	O
47	O
.	O
4	O
)<	O
0	O
.	O
001	O
Anxiolyticsc	O
33	O
.	O
1	O
(	O
23	O
.	O
7	O
;	O
46	O
.	O
2	O
)<	O
0	O
.	O
00132	O
.	O
2	O
(	O
23	O
.	O
1	O
;	O
45	O
.	O
0	O
)<	O
0	O
.	O
001	O
Sedativesd	O
22	O
.	O
6	O
(	O
15	O
.	O
6	O
;	O
30	O
.	O
8	O
)<	O
0	O
.	O
00123	O
.	O
1	O
(	O
16	O
.	O
8	O
;	O
31	O
.	O
7	O
)<	O
0	O
.	O
001Lag	O
2	O
,	O
N	O
=	O
654	O
observations	O
Antipsychoticse	O
13	O
.	O
3	O
(	O
8	O
.	O
3	O
;	O
21	O
.	O
4	O
)<	O
0	O
.	O
00113	O
.	O
5	O
(	O
8	O
.	O
1	O
;	O
22	O
.	O
3	O
)<	O
0	O
.	O
001	O
Antidepressantsf	O
15	O
.	O
5	O
(	O
9	O
.	O
9	O
;	O
24	O
.	O
2	O
)<	O
0	O
.	O
00116	O
.	O
0	O
(	O
10	O
.	O
2	O
;	O
25	O
.	O
3	O
)<	O
0	O
.	O
001	O
Anxiolyticsg	O
21	O
.	O
4	O
(	O
12	O
.	O
8	O
;	O
35	O
.	O
7	O
)<	O
0	O
.	O
00123	O
.	O
4	O
(	O
13	O
.	O
9	O
;	O
39	O
.	O
6	O
)<	O
0	O
.	O
001	O
Sedativesh	O
9	O
.	O
3	O
(	O
5	O
.	O
9	O
;	O
14	O
.	O
4	O
)<	O
0	O
.	O
0019	O
.	O
4	O
(	O
5	O
.	O
9	O
;	O
14	O
.	O
8	O
)<	O
0	O
.	O
001Lag	O
3	O
,	O
N	O
=	O
288	O
observations	O
Antipsychoticsi	O
16	O
.	O
5	O
(	O
7	O
.	O
5	O
;	O
36	O
.	O
3	O
)<	O
0	O
.	O
00117	O
.	O
9	O
(	O
7	O
.	O
5	O
;	O
42	O
.	O
4	O
)<	O
0	O
.	O
001	O
Antidepressantsj	O
10	O
.	O
0	O
(	O
4	O
.	O
9	O
;	O
20	O
.	O
4	O
)<	O
0	O
.	O
00112	O
.	O
6	O
(	O
5	O
.	O
8	O
;	O
27	O
.	O
2	O
)<	O
0	O
.	O
001	O
Anxiolyticsk	O
14	O
.	O
4	O
(	O
6	O
.	O
5	O
;	O
32	O
.	O
1	O
)<	O
0	O
.	O
00114	O
.	O
3	O
(	O
7	O
.	O
0	O
;	O
29	O
.	O
2	O
)<	O
0	O
.	O
001	O
Sedativesl	O
7	O
.	O
0	O
(	O
3	O
.	O
6	O
;	O
13	O
.	O
9	O
)<	O
0	O
.	O
0016	O
.	O
4	O
(	O
3	O
.	O
2	O
;	O
12	O
.	O
6	O
)<	O
0	O
.	O
001Lag	O
1	O
:	O
two	O
consecutive	O
assessment	O
time	O
pointsLag	O
2	O
:	O
one	O
time	O
point	O
between	O
selected	O
time	O
pointsLag	O
3	O
:	O
two	O
time	O
points	O
between	O
selected	O
time	O
points	O
aAdjusted	O
for	O
:	O
PSMS	O
score	O
,	O
NPI	O
Agitation	O
sub	O
-	O
syndrome	O
,	O
NPI	O
Psychosis	B-DS
sub	O
-	O
syndrome	O
,	O
NPI	O
Affective	O
sub	O
-	O
syndrome	O
,	O
NH	O
size	O
age	O
and	O
duration	O
in	O
NH	O
bAdjusted	O
for	O
:	O
PSMS	O
score	O
,	O
NPI	O
-	O
Affective	O
sub	O
-	O
syndrome	O
,	O
NPI	O
Apathy	O
and	O
duration	O
in	O
NH	O
cAdjusted	O
for	O
CDR	O
sum	O
of	O
boxes	O
,	O
NPI	O
-	O
Affective	O
sub	O
-	O
syndrome	O
and	O
level	O
of	O
education	O
dAdjusted	O
for	O
PSMS	O
score	O
,	O
NPI	O
Apathy	O
and	O
duration	O
in	O
NH	O
eAdjusted	O
for	O
PSMS	O
score	O
,	O
NPI	O
Psychosis	B-DS
sub	O
-	O
syndrome	O
,	O
NPI	O
Apathy	O
,	O
Type	O
of	O
nursing	O
home	O
and	O
age	O
fAdjusted	O
for	O
:	O
CDR	O
sum	O
of	O
boxes	O
,	O
PSMS	O
score	O
and	O
NPI	O
-	O
Affective	O
sub	O
-	O
syndrome	O
gAdjusted	O
for	O
CDR	O
sum	O
of	O
boxes	O
,	O
PSMS	O
score	O
and	O
level	O
of	O
education	O
hAdjusted	O
for	O
CDR	O
sum	O
of	O
boxes	O
,	O
PSMS	O
and	O
age	O
iAdjusted	O
for	O
PSMS	O
score	O
and	O
age	O
jAdjusted	O
for	O
:	O
CDR	O
sum	O
of	O
boxes	O
,	O
NPI	O
-	O
Affective	O
sub	O
-	O
syndrome	O
and	O
NPI	O
Apathy	O
kAdjusted	O
for	O
NPI	O
Agitation	O
sub	O
-	O
syndrome	O
,	O
NPI	O
Psychosis	B-DS
sub	O
-	O
syndrome	O
,	O
NPI	O
Affective	O
sub	O
-	O
syndrome	O
,	O
NPI	O
Apathy	O
,	O
level	O
of	O
education	O
and	O
Type	O
of	O
nursing	O
home	O
unit	O
lAdjusted	O
for	O
CDR	O
sum	O
of	O
boxes	O
,	O
NPI	O
Psychosis	B-DS
sub	O
-	O
syndrome	O
and	O
Nursing	O
home	O
size	O
Fig	O
.	O
2Illustration	O
of	O
OR	O
for	O
use	O
of	O
each	O
category	O
of	O
psychotropic	O
drugs	O
at	O
one	O
time	O
point	O
given	O
use	O
of	O
the	O
same	O
category	O
of	O
psychotropic	O
drug	O
at	O
an	O
earlier	O
time	O
point	O
by	O
distance	O
(	O
Lag	O
)	O
between	O
the	O
time	O
points	O
,	O
unadjusted	O
and	O
adjusted	O
.	O
a	O
Antipsychotics	O
;	O
b	O
Antidepressants	O
;	O
c	O
Anxiolytics	O
;	O
and	O
d	O
Sedatives	O

Factors	O
associated	O
with	O
use	O
of	O
psychotropic	O
drugs	O
at	O
two	O
consecutive	O
time	O
points	O

The	O
adjusted	O
risk	O
for	O
persistent	O
use	O
of	O
antipsychotics	O
at	O
two	O
consecutive	O
time	O
points	O
was	O
elevated	O
when	O
residents	O
had	O
higher	O
psychosis	B-DS
sub	O
-	O
syndrome	O
score	O
or	O
were	O
younger	O
,	O
were	O
male	O
or	O
had	O
a	O
longer	O
NH	O
stay	O
at	O
baseline	O
(	O
Table	O
4	O
).	O

The	O
adjusted	O
risk	O
for	O
persistent	O
use	O
of	O
antidepressants	O
was	O
elevated	O
when	O
residents	O
had	O
higher	O
P	O
-	O
ADL	O
functioning	O
(	O
lower	O
PSMS	O
score	O
)	O
or	O
higher	O
affective	O
sub	O
-	O
syndrome	O
score	O
.	O

The	O
adjusted	O
risk	O
for	O
persistent	O
use	O
of	O
anxiolytics	O
was	O
elevated	O
when	O
residents	O
had	O
higher	O
P	O
-	O
ADL	O
functioning	O
(	O
lower	O
PSMS	O
score	O
)	O
or	O
higher	O
affective	O
sub	O
-	O
syndrome	O
score	O
or	O
stayed	O
in	O
a	O
larger	O
NH	O
(	O
Table	O
5	O
).	O

The	O
adjusted	O
risk	O
for	O
persistent	O
use	O
of	O
sedatives	O
was	O
elevated	O
when	O
residents	O
had	O
better	O
cognitive	O
functioning	O
(	O
lower	O
CDR	O
sum	O
of	O
boxes	O
)	O
or	O
higher	O
affective	O
sub	O
-	O
syndrome	O
score	O
or	O
lower	O
apathy	O
symptom	O
score	O
.	O
Table	O
4Odds	O
of	O
use	O
of	O
Antipsychotics	O
or	O
Antidepressants	O
at	O
one	O
time	O
point	O
given	O
use	O
of	O
Antipsychotics	O
or	O
Antidepressants	O
at	O
the	O
previous	O
time	O
point	O
,	O
covariates	O
measured	O
at	O
the	O
“	O
previous	O
”	O
time	O
point	O
,	O
N	O
=	O
1406	O
observationsVariablesAntipsychoticsAntidepressantsUnadjustedAdjustedUnadjustedAdjustedOR	O
(	O
95	O
%	O
CI	O
)	O
P	O
-	O
valueOR	O
(	O
95	O
%	O
CI	O
)	O
P	O
-	O
valueOR	O
(	O
95	O
%	O
CI	O
)	O
P	O
-	O
valueOR	O
(	O
95	O
%	O
CI	O
)	O
P	O
-	O
valueAssessed	O
at	O
previous	O
time	O
point	O
CDR	O
sum	O
of	O
boxes1	O
.	O
04	O
(	O
1	O
.	O
002	O
;	O
1	O
.	O
07	O
)	O
0	O
.	O
0360	O
.	O
97	O
(	O
0	O
.	O
95	O
;	O
0	O
.	O
995	O
)	O
0	O
.	O
020	O
GMHR	O
Good1	O
.	O
25	O
(	O
0	O
.	O
66	O
;	O
2	O
.	O
37	O
)	O
0	O
.	O
4980	O
.	O
98	O
(	O
0	O
.	O
59	O
;	O
1	O
.	O
63	O
)	O
0	O
.	O
9340	O
.	O
63	O
(	O
0	O
.	O
35	O
;	O
1	O
.	O
12	O
)	O
3	O
0	O
.	O
111	O
Fairly	O
good1	O
.	O
11	O
(	O
0	O
.	O
63	O
;	O
1	O
.	O
98	O
)	O
0	O
.	O
7151	O
.	O
29	O
(	O
0	O
.	O
82	O
;	O
2	O
.	O
02	O
)	O
0	O
.	O
2730	O
.	O
92	O
(	O
0	O
.	O
56	O
;	O
1	O
.	O
51	O
)	O
8	O
0	O
.	O
745	O
Poor1	O
.	O
53	O
(	O
0	O
.	O
86	O
;	O
2	O
.	O
72	O
)	O
0	O
.	O
1511	O
.	O
62	O
(	O
1	O
.	O
03	O
;	O
2	O
.	O
56	O
)	O
0	O
.	O
0381	O
.	O
34	O
(	O
0	O
.	O
83	O
;	O
2	O
.	O
16	O
)	O
5	O
0	O
.	O
229	O
Very	O
Poor1	O
-	O
1	O
-	O
1	O
-	O
PSMS	O
score1	O
.	O
03	O
(	O
0	O
.	O
997	O
;	O
1	O
.	O
06	O
)	O
0	O
.	O
0730	O
.	O
96	O
(	O
0	O
.	O
94	O
;	O
0	O
.	O
98	O
)	O
0	O
.	O
0010	O
.	O
94	O
(	O
0	O
.	O
91	O
;	O
0	O
.	O
97	O
)	O
2	O
<	O
0	O
.	O
001	O
NPI	O
Agitation	O
sub	O
-	O
syndrome1	O
.	O
05	O
(	O
1	O
.	O
03	O
;	O
1	O
.	O
07	O
)<	O
0	O
.	O
0011	O
.	O
02	O
(	O
0	O
.	O
997	O
;	O
1	O
.	O
04	O
)	O
6	O
0	O
.	O
0930	O
.	O
997	O
(	O
0	O
.	O
98	O
;	O
1	O
.	O
01	O
)	O
0	O
.	O
714	O
NPI	O
Psychosis	B-DS
sub	O
-	O
syndrome1	O
.	O
09	O
(	O
1	O
.	O
06	O
;	O
1	O
.	O
12	O
)<	O
0	O
.	O
0011	O
.	O
06	O
(	O
1	O
.	O
03	O
;	O
1	O
.	O
10	O
)	O
2	O
0	O
.	O
0011	O
.	O
00	O
(	O
0	O
.	O
98	O
;	O
1	O
.	O
03	O
)	O
0	O
.	O
9150	O
.	O
97	O
(	O
0	O
.	O
95	O
;	O
1	O
.	O
00	O
)	O
4	O
0	O
.	O
060	O
NPI	O
Affective	O
sub	O
-	O
syndrome1	O
.	O
06	O
(	O
1	O
.	O
03	O
;	O
1	O
.	O
09	O
)<	O
0	O
.	O
0011	O
.	O
03	O
(	O
0	O
.	O
999	O
;	O
1	O
.	O
07	O
)	O
5	O
0	O
.	O
0601	O
.	O
08	O
(	O
1	O
.	O
05	O
;	O
1	O
.	O
10	O
)<	O
0	O
.	O
0011	O
.	O
08	O
(	O
1	O
.	O
05	O
;	O
1	O
.	O
11	O
)	O
1	O
<	O
0	O
.	O
001	O
NPI	O
Apathy1	O
.	O
07	O
(	O
1	O
.	O
03	O
;	O
1	O
.	O
12	O
)<	O
0	O
.	O
0010	O
.	O
99	O
(	O
0	O
.	O
96	O
;	O
1	O
.	O
03	O
)	O
0	O
.	O
732Assessed	O
at	O
baseline	O
Age0	O
.	O
95	O
(	O
0	O
.	O
93	O
;	O
0	O
.	O
97	O
)<	O
0	O
.	O
0010	O
.	O
95	O
(	O
0	O
.	O
93	O
;	O
0	O
.	O
97	O
)	O
1	O
<	O
0	O
.	O
0010	O
.	O
99	O
(	O
0	O
.	O
98	O
;	O
1	O
.	O
01	O
)	O
0	O
.	O
3170	O
.	O
98	O
(	O
0	O
.	O
97	O
;	O
1	O
.	O
00	O
)	O
6	O
0	O
.	O
056	O
Females0	O
.	O
56	O
(	O
0	O
.	O
40	O
;	O
0	O
.	O
80	O
)	O
0	O
.	O
0010	O
.	O
64	O
(	O
0	O
.	O
44	O
;	O
0	O
.	O
93	O
)	O
4	O
0	O
.	O
0191	O
.	O
38	O
(	O
1	O
.	O
02	O
;	O
1	O
.	O
87	O
)	O
0	O
.	O
0351	O
.	O
33	O
(	O
0	O
.	O
97	O
;	O
1	O
.	O
82	O
)	O
7	O
0	O
.	O
078	O
Education	O
(<=	O
10	O
years	O
)	O
0	O
.	O
97	O
(	O
0	O
.	O
68	O
;	O
1	O
.	O
39	O
)	O
0	O
.	O
8650	O
.	O
88	O
(	O
0	O
.	O
66	O
;	O
1	O
.	O
17	O
)	O
0	O
.	O
385	O
Duration	O
in	O
NH	O
(	O
LN	O
)	O
1	O
.	O
21	O
(	O
1	O
.	O
06	O
;	O
1	O
.	O
40	O
)	O
0	O
.	O
0071	O
.	O
21	O
(	O
1	O
.	O
05	O
;	O
1	O
.	O
40	O
)	O
3	O
0	O
.	O
0110	O
.	O
98	O
(	O
0	O
.	O
88	O
;	O
1	O
.	O
09	O
)	O
0	O
.	O
654	O
Nursing	O
home	O
size0	O
.	O
998	O
(	O
0	O
.	O
993	O
;	O
1	O
.	O
003	O
)	O
0	O
.	O
3821	O
.	O
00	O
(	O
0	O
.	O
998	O
;	O
1	O
.	O
01	O
)	O
0	O
.	O
347	O
Type	O
of	O
nursing	O
home	O
unit	O
RU1	O
-	O
1	O
-	O
REU0	O
.	O
57	O
(	O
0	O
.	O
10	O
;	O
3	O
.	O
41	O
)	O
0	O
.	O
5391	O
.	O
03	O
(	O
0	O
.	O
30	O
;	O
3	O
.	O
51	O
)	O
0	O
.	O
959	O
SCU1	O
.	O
24	O
(	O
0	O
.	O
78	O
;	O
1	O
.	O
97	O
)	O
0	O
.	O
3670	O
.	O
80	O
(	O
0	O
.	O
55	O
;	O
1	O
.	O
17	O
)	O
0	O
.	O
248	O
OU3	O
.	O
25	O
(	O
0	O
.	O
63	O
;	O
16	O
.	O
81	O
)	O
0	O
.	O
1601	O
.	O
13	O
(	O
0	O
.	O
28	O
;	O
4	O
.	O
61	O
)	O
10	O
.	O
865	O
RU	O
Regular	O
units	O
REU	O
rehabilitation	O
unit	O
SCU	O
special	O
care	O
unit	O
for	O
people	O
with	O
dementia	B-DS
OU	O
other	O
unitsThe	O
relative	O
importance	O
of	O
each	O
covariate	O
in	O
the	O
adjusted	O
models	O
is	O
included	O
with	O
a	O
number	O
after	O
the	O
95	O
%	O
CI	O
;	O
lowest	O
number	O
has	O
highest	O
importance	O
Table	O
5Odds	O
of	O
use	O
of	O
Anxiolytics	O
or	O
Sedatives	O
or	O
at	O
one	O
time	O
point	O
given	O
use	O
of	O
Anxiolytics	O
or	O
Sedatives	O
at	O
a	O
previous	O
time	O
point	O
,	O
covariates	O
measured	O
at	O
the	O
“	O
previous	O
”	O
time	O
point	O
,	O
N	O
=	O
1406	O
observationsVariablesAnxiolyticsSedativesUnadjustedAdjustedUnadjustedAdjustedOR	O
(	O
95	O
%	O
CI	O
)	O
P	O
-	O
valueOR	O
(	O
95	O
%	O
CI	O
)	O
P	O
-	O
valueOR	O
(	O
95	O
%	O
CI	O
)	O
P	O
-	O
valueOR	O
(	O
95	O
%	O
CI	O
)	O
P	O
-	O
valueAssessed	O
at	O
previous	O
time	O
point	O
CDR	O
sum	O
of	O
boxes0	O
.	O
96	O
(	O
0	O
.	O
94	O
;	O
0	O
.	O
99	O
)	O
0	O
.	O
0150	O
.	O
97	O
(	O
0	O
.	O
94	O
;	O
1	O
.	O
01	O
)	O
4	O
0	O
.	O
1250	O
.	O
94	O
(	O
0	O
.	O
91	O
;	O
0	O
.	O
97	O
)<	O
0	O
.	O
0010	O
.	O
94	O
(	O
0	O
.	O
91	O
;	O
0	O
.	O
97	O
)	O
1	O
<	O
0	O
.	O
001	O
GMHR	O
Good1	O
.	O
31	O
(	O
0	O
.	O
68	O
;	O
2	O
.	O
54	O
)	O
0	O
.	O
4211	O
.	O
20	O
(	O
0	O
.	O
65	O
;	O
2	O
.	O
23	O
)	O
Fairly	O
good1	O
.	O
56	O
(	O
0	O
.	O
87	O
;	O
2	O
.	O
81	O
)	O
0	O
.	O
1381	O
.	O
42	O
(	O
0	O
.	O
82	O
;	O
2	O
.	O
47	O
)	O
0	O
.	O
560	O
Poor1	O
.	O
83	O
(	O
1	O
.	O
01	O
;	O
3	O
.	O
30	O
)	O
0	O
.	O
0461	O
.	O
43	O
(	O
0	O
.	O
82	O
;	O
2	O
.	O
49	O
)	O
0	O
.	O
209	O
Very	O
Poor1	O
-	O
10	O
.	O
212	O
PSMS	O
score0	O
.	O
96	O
(	O
0	O
.	O
93	O
;	O
0	O
.	O
98	O
)	O
0	O
.	O
0020	O
.	O
96	O
(	O
0	O
.	O
93	O
;	O
0	O
.	O
99	O
)	O
3	O
0	O
.	O
0160	O
.	O
95	O
(	O
0	O
.	O
93	O
;	O
0	O
.	O
98	O
)-	O
NPI	O
Agitation	O
sub	O
-	O
syndrome1	O
.	O
00	O
(	O
0	O
.	O
98	O
;	O
1	O
.	O
02	O
)	O
0	O
.	O
9640	O
.	O
99	O
(	O
0	O
.	O
97	O
;	O
1	O
.	O
01	O
)	O
0	O
.	O
001	O
NPI	O
Psychosis	B-DS
sub	O
-	O
syndrome1	O
.	O
01	O
(	O
0	O
.	O
98	O
;	O
1	O
.	O
04	O
)	O
0	O
.	O
4511	O
.	O
00	O
(	O
0	O
.	O
97	O
;	O
1	O
.	O
04	O
)	O
0	O
.	O
358	O
NPI	O
Affective	O
sub	O
-	O
syndrome1	O
.	O
08	O
(	O
1	O
.	O
05	O
;	O
1	O
.	O
11	O
)<	O
0	O
.	O
0011	O
.	O
09	O
(	O
1	O
.	O
06	O
;	O
1	O
.	O
12	O
)	O
1	O
<	O
0	O
.	O
0011	O
.	O
04	O
(	O
1	O
.	O
01	O
;	O
1	O
.	O
07	O
)	O
0	O
.	O
8780	O
.	O
0051	O
.	O
06	O
(	O
1	O
.	O
03	O
;	O
1	O
.	O
09	O
)	O
2	O
<	O
0	O
.	O
001	O
NPI	O
Apathy1	O
.	O
01	O
(	O
0	O
.	O
97	O
;	O
1	O
.	O
05	O
)	O
0	O
.	O
6620	O
.	O
94	O
(	O
0	O
.	O
90	O
;	O
0	O
.	O
99	O
)	O
0	O
.	O
0120	O
.	O
95	O
(	O
0	O
.	O
90	O
;	O
0	O
.	O
996	O
)	O
4	O
0	O
.	O
034Assessed	O
at	O
baseline	O
Age0	O
.	O
997	O
(	O
0	O
.	O
98	O
;	O
1	O
.	O
02	O
)	O
0	O
.	O
7751	O
.	O
002	O
(	O
0	O
.	O
98	O
;	O
1	O
.	O
02	O
)	O
0	O
.	O
812	O
Females1	O
.	O
01	O
(	O
0	O
.	O
71	O
;	O
1	O
.	O
44	O
)	O
0	O
.	O
9671	O
.	O
28	O
(	O
0	O
.	O
89	O
;	O
1	O
.	O
83	O
)	O
0	O
.	O
182	O
Education	O
(<=	O
10	O
years	O
)	O
1	O
.	O
16	O
(	O
0	O
.	O
81	O
;	O
1	O
.	O
66	O
)	O
0	O
.	O
4160	O
.	O
82	O
(	O
0	O
.	O
59	O
;	O
1	O
.	O
15	O
)	O
0	O
.	O
2530	O
.	O
77	O
(	O
0	O
.	O
54	O
;	O
1	O
.	O
08	O
)	O
5	O
0	O
.	O
125	O
Duration	O
in	O
NH	O
(	O
LN	O
)	O
1	O
.	O
07	O
(	O
0	O
.	O
94	O
;	O
1	O
.	O
22	O
)	O
0	O
.	O
2921	O
.	O
12	O
(	O
0	O
.	O
98	O
;	O
1	O
.	O
28	O
)	O
5	O
0	O
.	O
1010	O
.	O
91	O
(	O
0	O
.	O
81	O
;	O
1	O
.	O
04	O
)	O
0	O
.	O
164	O
Nursing	O
home	O
size1	O
.	O
01	O
(	O
1	O
.	O
002	O
;	O
1	O
.	O
01	O
)	O
0	O
.	O
0041	O
.	O
007	O
(	O
1	O
.	O
002	O
;	O
1	O
.	O
011	O
)	O
2	O
0	O
.	O
0021	O
.	O
00	O
(	O
0	O
.	O
999	O
;	O
1	O
.	O
01	O
)	O
0	O
.	O
1091	O
.	O
004	O
(	O
1	O
.	O
00	O
;	O
1	O
.	O
008	O
)	O
3	O
0	O
.	O
072	O
Type	O
of	O
nursing	O
home	O
unit	O
RU1	O
-	O
1	O
-	O
REU0	O
.	O
18	O
(	O
0	O
.	O
02	O
;	O
1	O
.	O
83	O
)	O
0	O
.	O
1462	O
.	O
35	O
(	O
0	O
.	O
63	O
;	O
8	O
.	O
79	O
)	O
0	O
.	O
2060	O
.	O
7540	O
.	O
62	O
(	O
0	O
.	O
39	O
;	O
0	O
.	O
98	O
)	O
0	O
.	O
041	O
SCU0	O
.	O
93	O
(	O
0	O
.	O
58	O
;	O
1	O
.	O
49	O
)	O
OU2	O
.	O
96	O
(	O
0	O
.	O
54	O
;	O
16	O
.	O
13	O
)	O
0	O
.	O
2091	O
.	O
67	O
(	O
0	O
.	O
34	O
;	O
8	O
.	O
19	O
)	O
0	O
.	O
526	O
RU	O
Regular	O
units	O
REU	O
rehabilitation	O
unit	O
SCU	O
special	O
care	O
unit	O
for	O
people	O
with	O
dementia	B-DS
OU	O
other	O
unitsThe	O
relative	O
importance	O
of	O
each	O
covariate	O
in	O
the	O
adjusted	O
models	O
is	O
included	O
with	O
a	O
number	O
after	O
the	O
95	O
%	O
CI	O
;	O
lowest	O
number	O
has	O
highest	O
importance	O

In	O
a	O
subsequent	O
analysis	O
where	O
sub	O
-	O
syndrome	O
scores	O
of	O
NPS	O
at	O
the	O
first	O
time	O
point	O
were	O
replaced	O
by	O
change	O
in	O
sub	O
-	O
syndrome	O
score	O
between	O
the	O
two	O
assessments	O
,	O
we	O
found	O
no	O
association	O
between	O
change	O
in	O
the	O
sub	O
-	O
syndrome	O
scores	O
of	O
NPS	O
and	O
persistent	O
use	O
of	O
antipsychotic	O
drugs	O
,	O
antidepressants	O
,	O
anxiolytics	O
or	O
sedatives	O
.	O

Discussion	O

In	O
this	O
Norwegian	O
NH	O
study	O
,	O
the	O
prevalence	O
and	O
persistent	O
use	O
of	O
PTD	O
at	O
two	O
consecutive	O
time	O
points	O
was	O
high	O
,	O
both	O
for	O
residents	O
with	O
and	O
without	O
dementia	B-DS
,	O
except	O
for	O
use	O
of	O
an	O
anti	O
-	O
dementia	B-DS
drug	O
.	O

Close	O
to	O
three	O
-	O
quarters	O
of	O
the	O
dementia	B-DS
and	O
two	O
-	O
thirds	O
of	O
non	O
-	O
dementia	B-DS
residents	O
used	O
PTD	O
at	O
baseline	O
of	O
the	O
data	O
collection	O
.	O

Persistent	O
use	O
of	O
anxiolytics	O
was	O
more	O
common	O
in	O
residents	O
without	O
dementia	B-DS
.	O

The	O
persistent	O
use	O
decreased	O
gradually	O
when	O
the	O
distance	O
between	O
the	O
assessment	O
time	O
points	O
increased	O
(	O
Lags	O
2	O
and	O
3	O
),	O
with	O
the	O
exception	O
of	O
the	O
use	O
of	O
antipsychotics	O
drugs	O
.	O

More	O
severe	O
NPS	O
were	O
associated	O
with	O
persistent	O
use	O
of	O
antipsychotics	O
drugs	O
,	O
antidepressants	O
,	O
anxiolytics	O
and	O
sedatives	O
at	O
the	O
next	O
time	O
point	O
,	O
but	O
change	O
in	O
NPS	O
between	O
the	O
time	O
points	O
was	O
not	O
associated	O
with	O
persistent	O
use	O
of	O
PTD	O
.	O

Better	O
P	O
-	O
ADL	O
functioning	O
(	O
lower	O
PSMS	O
score	O
)	O
was	O
associated	O
with	O
persistent	O
use	O
of	O
antidepressants	O
and	O
anxiolytics	O
.	O

Furthermore	O
,	O
less	O
severe	B-DS
dementia	I-DS
was	O
associated	O
with	O
persistent	O
use	O
of	O
sedatives	O
.	O

Of	O
the	O
organizational	O
variables	O
included	O
in	O
the	O
analysis	O
,	O
we	O
found	O
that	O
a	O
longer	O
stay	O
in	O
NH	O
increased	O
the	O
odds	O
for	O
persistent	O
use	O
of	O
antipsychotics	O
at	O
two	O
consecutive	O
time	O
points	O
and	O
staying	O
in	O
a	O
larger	O
-	O
sized	O
NH	O
increased	O
the	O
odds	O
for	O
persistent	O
use	O
of	O
anxiolytics	O
.	O

Use	O
of	O
antipsychotics	O

The	O
study	O
found	O
that	O
the	O
prevalence	O
of	O
atypical	O
antipsychotics	O
was	O
higher	O
in	O
residents	O
with	O
dementia	B-DS
than	O
in	O
residents	O
without	O
,	O
but	O
only	O
for	O
the	O
first	O
three	O
time	O
points	O
.	O

Use	O
of	O
conventional	O
antipsychotics	O
did	O
not	O
differ	O
between	O
residents	O
with	O
or	O
without	O
dementia	B-DS
at	O
any	O
time	O
point	O
.	O

The	O
persistence	O
in	O
use	O
of	O
both	O
atypical	O
and	O
conventional	O
antipsychotics	O
at	O
two	O
consecutive	O
time	O
points	O
was	O
high	O
(>	O
50	O
%)	O
during	O
the	O
entire	O
follow	O
-	O
up	O
period	O
of	O
72	O
months	O
for	O
both	O
groups	O
of	O
residents	O
.	O

A	O
small	O
6	O
-	O
month	O
follow	O
-	O
up	O
study	O
of	O
newly	O
arrived	O
NH	O
residents	O
in	O
Australia	O
has	O
previously	O
reported	O
the	O
persistence	O
of	O
antipsychotics	O
to	O
be	O
equally	O
high	O
[	O
49	O
].	O

Given	O
the	O
strong	O
evidence	O
on	O
the	O
increased	O
mortality	O
risk	O
associated	O
with	O
use	O
of	O
conventional	O
antipsychotics	O
in	O
people	O
with	O
dementia	B-DS
it	O
is	O
rather	O
surprising	O
to	O
see	O
that	O
they	O
are	O
still	O
used	O
to	O
that	O
extent	O
.	O

These	O
findings	O
are	O
alarming	O
,	O
since	O
the	O
duration	O
of	O
such	O
treatment	O
should	O
be	O
as	O
short	O
as	O
possible	O
[	O
32	O
].	O

In	O
the	O
present	O
adjusted	O
logistic	O
regression	O
analysis	O
for	O
persistent	O
use	O
of	O
antipsychotic	O
drugs	O
at	O
two	O
consecutive	O
time	O
points	O
,	O
higher	O
severity	O
of	O
psychosis	B-DS
increased	O
the	O
risk	O
for	O
persistent	O
use	O
of	O
antipsychotics	O
.	O

However	O
,	O
it	O
is	O
surprising	O
that	O
in	O
the	O
exploratory	O
analysis	O
,	O
a	O
change	O
in	O
NPS	O
was	O
not	O
associated	O
with	O
persistent	O
use	O
of	O
antipsychotics	O
.	O

Clinical	O
recommendations	O
have	O
highlighted	O
the	O
need	O
for	O
clinicians	O
to	O
monitor	O
NPS	O
closely	O
and	O
consider	O
discontinuing	O
treatment	O
with	O
antipsychotics	O
when	O
an	O
obvious	O
treatment	O
effect	O
does	O
not	O
occur	O
or	O
the	O
residents	O
have	O
side	O
effects	O
due	O
to	O
the	O
treatment	O
[	O
32	O
].	O

It	O
could	O
be	O
that	O
people	O
receiving	O
PTD	O
had	O
more	O
severe	O
symptoms	O
prior	O
to	O
drug	O
initiation	O
.	O

Also	O
,	O
it	O
could	O
be	O
that	O
antipsychotics	O
were	O
described	O
as	O
unspecific	O
sedatives	O
.	O

Very	O
few	O
studies	O
have	O
examined	O
variables	O
associated	O
with	O
persistent	O
use	O
of	O
antipsychotics	O
in	O
NH	O
residents	O
[	O
46	O
,	O
52	O
],	O
but	O
none	O
of	O
these	O
studies	O
have	O
explicitly	O
explored	O
the	O
importance	O
of	O
NPS	O
in	O
the	O
persistent	O
use	O
of	O
antipsychotic	O
drugs	O
.	O

However	O
,	O
cross	O
-	O
sectional	O
studies	O
have	O
explored	O
the	O
association	O
between	O
NPS	O
and	O
use	O
of	O
antipsychotic	O
drugs	O
and	O
found	O
that	O
higher	O
total	O
symptom	O
load	O
[	O
80	O
]	O
and	O
more	O
severe	O
psychosis	B-DS
sub	O
-	O
syndromes	O
symptoms	O
were	O
associated	O
with	O
use	O
of	O
antipsychotics	O
[	O
11	O
,	O
14	O
,	O
81	O
,	O
82	O
].	O

In	O
the	O
adjusted	O
logistic	O
regression	O
analysis	O
of	O
use	O
of	O
antipsychotics	O
,	O
younger	O
age	O
and	O
male	O
gender	O
increased	O
the	O
risk	O
for	O
persistent	O
use	O
of	O
antipsychotics	O
.	O

In	O
contrast	O
,	O
a	O
small	O
Swedish	O
6	O
-	O
month	O
follow	O
-	O
up	O
study	O
in	O
NH	O
residents	O
with	O
dementia	B-DS
did	O
not	O
find	O
age	O
,	O
gender	O
or	O
other	O
personal	O
characteristics	O
of	O
the	O
residents	O
such	O
as	O
P	O
-	O
ADL	O
or	O
cognitive	O
functioning	O
important	O
for	O
persistent	O
use	O
of	O
antipsychotics	O
[	O
52	O
].	O

Our	O
finding	O
may	O
partly	O
be	O
explained	O
by	O
age	O
and	O
gender	O
-	O
based	O
expressions	O
of	O
behavioral	O
symptoms	O
[	O
80	O
]	O
not	O
captured	O
by	O
the	O
NPS	O
.	O

Male	O
and	O
younger	O
residents	O
may	O
be	O
experienced	O
as	O
more	O
threatening	O
in	O
their	O
verbal	O
or	O
physical	O
expressions	O
and	O
are	O
physically	O
stronger	O
compared	O
to	O
women	B-OG
and	O
older	O
residents	O
,	O
and	O
for	O
this	O
reason	O
may	O
be	O
put	O
on	O
antipsychotic	O
drugs	O
.	O

In	O
line	O
with	O
our	O
results	O
,	O
cross	O
-	O
sectional	O
studies	O
of	O
use	O
of	O
antipsychotics	O
in	O
NH	O
residents	O
have	O
found	O
that	O
younger	O
residents	O
[	O
4	O
,	O
8	O
,	O
15	O
,	O
22	O
,	O
80	O
,	O
82	O
,	O
83	O
]	O
and	O
male	O
residents	O
[	O
5	O
,	O
80	O
,	O
84	O
]	O
are	O
more	O
likely	O
to	O
receive	O
antipsychotics	O
.	O

Persistent	O
use	O
of	O
antipsychotics	O
has	O
been	O
reported	O
to	O
be	O
more	O
frequent	O
in	O
regular	O
care	O
units	O
than	O
in	O
SCU	O
[	O
46	O
].	O

In	O
the	O
present	O
study	O
we	O
did	O
not	O
find	O
an	O
association	O
between	O
the	O
type	O
of	O
care	O
unit	O
and	O
persistent	O
use	O
of	O
antipsychotics	O
.	O

In	O
Norway	O
,	O
SCUs	O
have	O
residents	O
with	O
more	O
severe	O
NPS	O
than	O
other	O
units	O
,	O
which	O
could	O
explain	O
our	O
result	O
[	O
30	O
].	O

However	O
,	O
we	O
found	O
that	O
residents	O
with	O
a	O
longer	O
stay	O
in	O
NH	O
at	O
baseline	O
had	O
an	O
increased	O
likelihood	O
of	O
being	O
persistent	O
users	O
of	O
antipsychotics	O
.	O

We	O
do	O
not	O
have	O
a	O
firm	O
explanation	O
for	O
this	O
,	O
but	O
it	O
may	O
be	O
that	O
newly	O
arrived	O
NH	O
residents	O
receive	O
more	O
attention	O
from	O
the	O
staff	O
or	O
respond	O
better	O
to	O
care	O
that	O
is	O
intended	O
to	O
reduce	O
stress	O
,	O
strain	O
and	O
symptoms	O
related	O
to	O
dementia	B-DS
.	O

Use	O
of	O
antidepressants	O

We	O
found	O
,	O
in	O
line	O
with	O
other	O
studies	O
,	O
that	O
antidepressants	O
were	O
the	O
most	O
frequently	O
used	O
PTD	O
in	O
NH	O
residents	O
[	O
48	O
,	O
49	O
]	O
and	O
that	O
the	O
frequency	O
did	O
not	O
differ	O
between	O
residents	O
with	O
or	O
without	O
dementia	B-DS
[	O
85	O
].	O

The	O
persistence	O
of	O
use	O
of	O
antidepressants	O
was	O
also	O
high	O
[	O
49	O
].	O

As	O
we	O
could	O
expect	O
,	O
those	O
with	O
more	O
severe	O
affective	O
symptoms	O
had	O
higher	O
odds	O
for	O
persistent	O
use	O
of	O
antidepressants	O
.	O

This	O
result	O
is	O
in	O
line	O
with	O
cross	O
-	O
sectional	O
studies	O
of	O
associations	O
for	O
use	O
of	O
antidepressants	O
[	O
11	O
,	O
15	O
,	O
81	O
].	O

Even	O
so	O
,	O
the	O
efficacy	O
of	O
antidepressants	O
in	O
treating	O
depression	B-DS
in	O
persons	O
with	O
dementia	B-DS
is	O
uncertain	O
.	O

The	O
high	O
prevalence	O
and	O
persistence	O
of	O
antidepressants	O
use	O
may	O
indicate	O
that	O
these	O
drugs	O
also	O
are	O
used	O
for	O
the	O
treatment	O
of	O
agitation	O
.	O

Better	O
performance	O
in	O
P	O
-	O
ADL	O
was	O
more	O
likely	O
to	O
be	O
associated	O
with	O
persistent	O
antidepressant	O
users	O
.	O

We	O
do	O
not	O
have	O
a	O
firm	O
explanation	O
for	O
this	O
,	O
but	O
it	O
may	O
be	O
that	O
those	O
with	O
better	O
P	O
-	O
ADL	O
also	O
have	O
a	O
better	O
ability	O
to	O
express	O
their	O
emotional	O
state	O
.	O

Use	O
of	O
anxiolytics	O
,	O
sedatives	O
and	O
anti	O
-	O
dementia	B-DS
drugs	O

The	O
prevalence	O
of	O
anxiolytics	O
in	O
the	O
NH	O
residents	O
varied	O
between	O
20	O
and	O
40	O
%,	O
and	O
was	O
significantly	O
higher	O
in	O
residents	O
without	O
dementia	B-DS
,	O
while	O
the	O
persistent	O
use	O
of	O
anxiolytics	O
in	O
adjusted	O
analysis	O
was	O
not	O
explained	O
by	O
the	O
severity	O
of	O
dementia	B-DS
.	O

As	O
for	O
antidepressants	O
,	O
persistent	O
use	O
of	O
anxiolytics	O
was	O
explained	O
by	O
more	O
severe	O
affective	O
symptoms	O
and	O
better	O
P	O
-	O
ADL	O
functioning	O
,	O
but	O
not	O
by	O
change	O
in	O
affective	O
sub	O
-	O
syndrome	O
symptoms	O
between	O
time	O
points	O
.	O

The	O
size	O
of	O
the	O
NH	O
was	O
associated	O
with	O
persistent	O
use	O
of	O
anxiolytics	O
.	O

We	O
speculate	O
that	O
staff	O
distress	O
[	O
81	O
],	O
registered	O
nursing	O
hours	O
per	O
resident	O
[	O
86	O
]	O
and	O
other	O
organizational	O
factors	O
[	O
5	O
]	O
that	O
we	O
have	O
not	O
measured	O
may	O
be	O
related	O
to	O
NH	O
size	O
,	O
quality	O
of	O
care	O
and	O
use	O
or	O
persistent	O
use	O
of	O
anxiolytics	O
.	O

Use	O
of	O
sedatives	O
was	O
higher	O
among	O
residents	O
without	O
dementia	B-DS
than	O
residents	O
with	O
dementia	B-DS
and	O
varied	O
between	O
19	O
and	O
26	O
%	O
in	O
residents	O
with	O
dementia	B-DS
and	O
between	O
32	O
and	O
40	O
%	O
in	O
residents	O
without	O
dementia	B-DS
.	O

A	O
possible	O
explanation	O
may	O
be	O
that	O
residents	O
without	O
dementia	B-DS
are	O
more	O
vulnerable	O
to	O
disturbances	O
in	O
the	O
NH	O
environment	O
and	O
at	O
the	O
same	O
time	O
may	O
be	O
more	O
able	O
to	O
ask	O
for	O
sedatives	O
than	O
residents	O
with	O
dementia	B-DS
.	O

The	O
prevalence	O
of	O
anti	O
-	O
dementia	B-DS
drugs	O
use	O
was	O
at	O
baseline	O
11	O
.	O
3	O
%	O
for	O
all	O
residents	O
and	O
as	O
expected	O
the	O
prevalence	O
of	O
such	O
use	O
declined	O
at	O
each	O
of	O
the	O
follow	O
-	O
ups	O
and	O
at	O
the	O
fifth	O
assessment	O
no	O
one	O
used	O
anti	O
-	O
dementia	B-DS
drugs	O
.	O

At	O
the	O
four	O
first	O
assessment	O
time	O
points	O
between	O
1	O
.	O
9	O
to	O
2	O
.	O
2	O
%	O
of	O
residents	O
with	O
CDR	O
less	O
than	O
1	O
were	O
prescribed	O
anti	O
-	O
dementia	B-DS
drugs	O
.	O

This	O
may	O
indicate	O
that	O
the	O
NH	O
physicians	O
have	O
prescribed	O
the	O
anti	O
-	O
dementia	B-DS
drugs	O
without	O
having	O
a	O
dementia	B-DS
diagnosis	O
(	O
P70	O
),	O
but	O
the	O
physicians	O
may	O
have	O
used	O
the	O
diagnosis	O
cognitive	O
problems	O
(	O
P20	O
)	O
as	O
an	O
indication	O
for	O
prescribing	O
the	O
drug	O
.	O

This	O
is	O
quite	O
common	O
in	O
Norway	O
.	O

However	O
,	O
in	O
a	O
recent	O
Norwegian	O
study	O
it	O
was	O
found	O
that	O
a	O
substantial	O
number	O
of	O
persons	O
who	O
purchased	O
anti	O
-	O
dementia	B-DS
drugs	O
had	O
no	O
diagnosis	O
of	O
dementia	B-DS
or	O
cognitive	O
problems	O
registered	O
in	O
the	O
primary	O
health	O
care	O
service	O
system	O
[	O
87	O
].	O

Strength	O
and	O
limitations	O

The	O
study	O
has	O
significant	O
strengths	O
.	O

Firstly	O
,	O
all	O
nurses	O
participating	O
in	O
the	O
data	O
collection	O
participated	O
in	O
a	O
2	O
-	O
day	O
educational	O
course	O
to	O
ensure	O
that	O
they	O
had	O
adequate	O
knowledge	O
prior	O
to	O
collecting	O
data	O
for	O
this	O
study	O
and	O
participated	O
in	O
a	O
1	O
-	O
day	O
educational	O
course	O
before	O
the	O
follow	O
-	O
up	O
data	O
collections	O
.	O

This	O
ensured	O
high	O
data	O
quality	O
.	O

Secondly	O
,	O
a	O
large	O
sample	O
size	O
allowed	O
us	O
to	O
adjust	O
for	O
many	O
potentially	O
important	O
variables	O
,	O
such	O
as	O
health	O
and	O
demographic	O
factors	O
.	O

Furthermore	O
,	O
this	O
study	O
benefits	O
from	O
the	O
inclusion	O
of	O
NHs	O
located	O
in	O
a	O
large	O
part	O
of	O
the	O
country	O
.	O

However	O
,	O
we	O
cannot	O
guarantee	O
that	O
the	O
sample	O
is	O
representative	O
for	O
Norwegian	O
NH	O
residents	O
since	O
inclusion	O
was	O
not	O
based	O
on	O
random	O
selection	O
from	O
all	O
NHs	O
in	O
Norway	O
.	O

The	O
study	O
has	O
some	O
limitations	O
.	O

Firstly	O
,	O
the	O
data	O
from	O
the	O
present	O
study	O
is	O
quite	O
old	O
since	O
data	O
collection	O
started	O
in	O
2004	O
,	O
and	O
thus	O
,	O
may	O
not	O
represent	O
medication	O
use	O
patterns	O
in	O
Norwegian	O
NHs	O
of	O
today	O
.	O

Secondly	O
,	O
a	O
high	O
drop	O
-	O
out	O
rate	O
mainly	O
due	O
to	O
death	O
might	O
have	O
introduced	O
some	O
bias	O
into	O
the	O
results	O
.	O

However	O
,	O
this	O
methodological	O
problem	O
is	O
inherent	O
to	O
most	O
longitudinal	O
NH	O
studies	O
.	O

Also	O
,	O
we	O
used	O
linear	O
mixed	O
models	O
that	O
include	O
all	O
available	O
data	O
(	O
data	O
from	O
drop	O
-	O
outs	O
as	O
well	O
)	O
in	O
the	O
analysis	O
.	O

Due	O
to	O
the	O
low	O
number	O
of	O
participants	O
at	O
the	O
end	O
of	O
the	O
follow	O
-	O
up	O
period	O
,	O
the	O
analysis	O
of	O
persistence	O
was	O
limited	O
to	O
three	O
lags	O
only	O
.	O

Thirdly	O
,	O
the	O
time	O
intervals	O
between	O
the	O
assessments	O
varied	O
somewhat	O
among	O
participants	O
.	O

However	O
,	O
this	O
affects	O
the	O
results	O
only	O
minimally	O
,	O
since	O
the	O
time	O
intervals	O
between	O
assessments	O
were	O
quite	O
long	O
and	O
not	O
used	O
in	O
the	O
models	O
explicitly	O
,	O
only	O
as	O
lags	O
.	O

In	O
the	O
present	O
study	O
the	O
time	O
intervals	O
between	O
the	O
assessments	O
were	O
1	O
year	O
or	O
more	O
and	O
due	O
to	O
the	O
study	O
design	O
,	O
we	O
do	O
not	O
know	O
whether	O
there	O
were	O
changes	O
in	O
PTD	O
use	O
between	O
assessments	O
.	O

Fourthly	O
,	O
there	O
is	O
a	O
limitation	O
on	O
the	O
accuracy	O
of	O
dementia	B-DS
diagnoses	O
,	O
since	O
dementia	B-DS
and	O
degree	O
of	O
dementia	B-DS
are	O
based	O
on	O
the	O
CDR	O
rating	O
of	O
several	O
assessors	O
and	O
the	O
fact	O
that	O
a	O
CDR	O
assessment	O
was	O
used	O
,	O
and	O
not	O
a	O
standardized	O
dementia	B-DS
diagnosis	O
,	O
including	O
neuropsychological	O
tests	O
.	O

A	O
large	O
number	O
of	O
residents	O
with	O
a	O
CDR	O
score	O
of	O
3	O
could	O
not	O
be	O
tested	O
with	O
any	O
dementia	B-DS
tests	O
such	O
as	O
the	O
Mini	O
Mental	O
Status	O
Examination	O
or	O
the	O
Clock	O
Drawing	O
Test	O
.	O

However	O
,	O
CDR	O
is	O
an	O
accepted	O
assessment	O
tool	O
and	O
is	O
commonly	O
used	O
in	O
epidemiological	O
NH	O
studies	O
to	O
identify	O
dementia	B-DS
and	O
measure	O
the	O
severity	O
of	O
dementia	B-DS
[	O
65	O
,	O
88	O
],	O
and	O
the	O
agreement	O
between	O
CDR	O
and	O
a	O
diagnostic	O
assessment	O
according	O
to	O
the	O
ICD	O
-	O
10	O
is	O
high	O
[	O
62	O
].	O

Conclusion	O

Psychotropic	O
drugs	O
were	O
frequently	O
used	O
as	O
a	O
long	O
-	O
term	O
treatment	O
among	O
NH	O
residents	O
and	O
were	O
associated	O
with	O
severity	O
of	O
neuropsychiatric	O
symptoms	O
,	O
but	O
not	O
with	O
severity	O
of	O
dementia	B-DS
.	O

The	O
high	O
prevalence	O
and	O
persistence	O
of	O
psychotropic	O
drug	O
use	O
may	O
indicate	O
that	O
the	O
treatment	O
is	O
not	O
in	O
line	O
with	O
current	O
treatment	O
recommendation	O
.	O

It	O
is	O
important	O
that	O
clinicians	O
monitor	O
effects	O
and	O
side	O
effects	O
of	O
PTD	O
treatment	O
closely	O
and	O
stop	O
treatment	O
when	O
the	O
risk	O
is	O
not	O
balanced	O
by	O
considerable	O
benefits	O
to	O
the	O
NH	O
resident	O
.	O

